#BEGIN_DRUGCARD DB00622

# AHFS_Codes:
24:28.08

# ATC_Codes:
C08CA04

# Absorption:
While nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.

# Biotransformation:
Nicardipine HCl is metabolized extensively by the liver.

# Brand_Mixtures:
Not Available

# Brand_Names:
Cardene
Cardene IV
Cardene SR

# CAS_Registry_Number:
55985-32-5

# ChEBI_ID:
Not Available

# Chemical_Formula:
C26H29N3O6

# Chemical_IUPAC_Name:
3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2162733

# Description:
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]

# Dosage_Forms:
Capsule	Oral
Capsule	Oral
Capsule, extended release	Oral
Capsule, extended release	Oral
Capsule, extended release	Oral
Injection, solution, concentrate	Intravenous

# Drug_Category:
Antiarrhythmic Agents
Antihypertensive Agents
Calcium Channel Blockers
Dihydropyridines
Vasodilator Agents

# Drug_Interactions:
Bromazepam	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nicardipine is initiated, discontinued or dose changed. Dosage adjustments may be required.
Cyclosporine	Nicardipine increases the effect and toxicity of cyclosporine
Dantrolene	Nicardipine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nicardipine is initiated, discontinued or dose changed.
Quinupristin	This combination presents an increased risk of toxicity
Tacrolimus	The calcium channel blocker, Nicardipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nicardipine therapy is initiated, discontinued or altered.
Tadalafil	Nicardipine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
Tamoxifen	Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed.
Tamsulosin	Nicardipine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nicardipine is initiated, discontinued, or dose changed.
Telithromycin	Co-administration may result in altered plasma concentrations of Nicardipine and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.
Temsirolimus	Nicardipine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
Teniposide	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nicardipine is initiated, discontinued or dose changed.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Thiopental	The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nicardipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nicardipine if Thiopental is initiated, discontinued or dose changed.
Tiagabine	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nicardipine is initiated, discontinued or dose changed.
Tipranavir	Tipranavir, co-administered with Ritonavir, may alter the concentration of Nicardipine. Monitor for efficacy and adverse/toxic effects of Nicardipine.
Tolbutamide	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed.
Tolterodine	Nicardipine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
Topotecan	The p-glycoprotein inhibitor, Nicardipine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
Torasemide	Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Nicardipine is initiated, discontinued or dose changed.
Tramadol	Nicardipine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Nicardipine may decrease the effect of Tramadol by decreasing active metabolite production.
Trazodone	The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed.
Treprostinil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Trimethoprim	The strong CYP2C9 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Nicardipine is initiated, discontinued or dose changed.
Trimipramine	The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nicardipine is initiated, discontinued or dose changed.
Vardenafil	Nicardipine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
Venlafaxine	Nicardipine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nicardipine is initiated, discontinued, or dose changed.
Verapamil	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nicardipine is initiated, discontinued or dose changed.
Vinblastine	Nicardipine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nicardipine is initiated, discontinued or dose changed.
Vincristine	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nicardipine is initiated, discontinued or dose changed.
Vinorelbine	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nicardipine is initiated, discontinued or dose changed.
Voriconazole	Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nicardipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole and nicardipine if concomitant therapy is initiated, discontinued or doses are changed.
Warfarin	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed.
Zafirlukast	Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if nicardipine is initiated, discontinued or dose changed.
Zolpidem	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nicardipine is initiated, discontinued or dose changed.
Zonisamide	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nicardipine is initiated, discontinued or dose changed.
Zopiclone	Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nicardipine is initiated, discontinued or dose changed.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
3.82

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
2.2 mg/L

# Food_Interactions:
Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Nicardipine

# HET_ID:
Not Available

# Half_Life:
8.6 hours

# InChI_Identifier:
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3

# InChI_Key:
InChIKey=ZBBHBTPTTSWHBA-UHFFFAOYSA-N

# Indication:
Used for the management of patients with chronic stable angina and for the treatment of hypertension.

# KEGG_Compound_ID:
C07264

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
622

# Mechanism_Of_Action:
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

# Melting_Point:
136-138 Â°C

# Molecular_Weight_Avg:
479.525

# Molecular_Weight_Mono:
479.205635675

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450620

# Pharmacology:
Nicardipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nicardipine is similar to other peripheral vasodilators. Nicardipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

# Predicted_LogP_Hydrophobicity:
4.34

# Predicted_LogS:
-5.3

# Predicted_Water_Solubility:
2.47e-03 g/l

# Primary_Accession_No:
DB00622

# Protein_Binding:
>95%

# PubChem_Compound_ID:
4474

# PubChem_Substance_ID:
46504482

# RxList_Link:
http://www.rxlist.com/cgi/generic/nicardipine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00088

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Nicardipine HCl
Nicardipino [INN-Spanish]
Nicardipinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Oral LD<sub>50</sub> Rat = 184 mg/kg, Oral LD<sub>50</sub> Mouse = 322 mg/kg

# Update_Date:
2013-02-08 16:19:30 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nicardipine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_1_ID:
4118

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_2_ID:
4119

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_3_ID:
4512

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_4_ID:
4757

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_5_ID:
4924

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P10632

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_6_ID:
6013

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P05181

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_7_ID:
6016

# Phase_1_Metabolizing_Enzyme_7_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
P33261

# Phase_1_Metabolizing_Enzyme_8_Gene_Name:
CYP2B6

# Phase_1_Metabolizing_Enzyme_8_ID:
6030

# Phase_1_Metabolizing_Enzyme_8_Name:
Cytochrome P450 2B6

# Phase_1_Metabolizing_Enzyme_8_Protein_Sequence:
>Cytochrome P450 2B6
MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFRE
KYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNR
WKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIIC
SIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQE
INAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGT
ETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFS
DLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGAL
KKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKI
PPTYQIRFLPR

# Phase_1_Metabolizing_Enzyme_8_SwissProt_ID:
P20813

# Drug_Target_10_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
2981533	Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
CHRM1

# Drug_Target_10_GenBank_ID_Gene:
X52068

# Drug_Target_10_GenBank_ID_Protein:
34451

# Drug_Target_10_GeneCard_ID:
CHRM1

# Drug_Target_10_Gene_Name:
CHRM1

# Drug_Target_10_Gene_Sequence:
>1383 bp
ATGAACACTTCAGCCCCACCTGCTGTCAGCCCCAACATCACCGTCCTGGCACCAGGAAAG
GGTCCCTGGCAAGTGGCCTTCATTGGGATCACCACGGGCCTCCTGTCGCTAGCCACAGTG
ACAGGCAACCTGCTGGTACTCATCTCTTTCAAGGTCAACACGGAGCTCAAGACAGTCAAT
AACTACTTCCTGCTGAGCCTGGCCTGTGCTGACCTCATCATCGGTACCTTCTCCATGAAC
CTCTATACCACGTACCTGCTCATGGGCCACTGGGCTCTGGGCACGCTGGCTTGTGACCTC
TGGCTGGCCCTGGACTATGTGGCCAGCAATGCCTCCGTCATGAATCTGCTGCTCATCAGC
TTTGACCGCTACTTCTCCGTGACTCGGCCCCTGAGCTACCGTGCCAAGCGCACACCCCGC
CGGGCAGCTCTGATGATCGGCCTGGCCTGGCTGGTTTCCTTTGTGCTCTGGGCCCCAGCC
ATCCTCTTCTGGCAGTACCTGGTAGGGGAGCGGACAGTGCTAGCTGGGCAGTGCTACATC
CAGTTCCTCTCCCAGCCCATCATCACCTTTGGCACAGCCATGGCTGCCTTCTACCTCCCT
GTCACAGTCATGTGCACGCTCTACTGGCGCATCTACCGGGAGACAGAGAACCGAGCACGG
GAGCTGGCAGCCCTTCAGGGCTCCGAGACGCCAGGCAAAGGGGGTGGCAGCAGCAGCAGC
TCAGAGAGGTCTCAGCCAGGGGCTGAGGGCTCACCAGAGACTCCTCCAGGCCGCTGCTGT
CGCTGCTGCCGGGCCCCCAGGCTGCTGCAGGCCTACAGCTGGAAGGAAGAAGAGGAAGAG
GACGAAGGCTCCATGGAGTCCCTCACATCCTCAGAGGGAGAGGAGCCTGGCTCCGAAGTG
GTGATCAAGATGCCAATGGTGGACCCCGAGGCACAGGCCCCCACCAAGCAGCCCCCACGG
AGCTCCCCAAATACAGTCAAGAGGCCGACTAAGAAAGGGCGTGATCGAGCTGGCAAGGGC
CAGAAGCCCCGTGGAAAGGAGCAGCTGGCCAAGCGGAAGACCTTCTCGCTGGTCAAGGAG
AAGAAGGCGGCTCGGACCCTGAGTGCCATCCTCCTGGCCTTCATCCTCACCTGGACACCG
TACAACATCATGGTGCTGGTGTCCACCTTCTGCAAGGACTGTGTTCCCGAGACCCTGTGG
GAGCTGGGCTACTGGCTGTGCTACGTCAACAGCACCATCAACCCCATGTGCTACGCACTC
TGCAACAAAGCCTTCCGGGACACCTTTCGCCTGCTGCTGCTTTGCCGCTGGGACAAGAGA
CGCTGGCGCAAGATCCCCAAGCGCCCTGGCTCCGTGCACCGCACTCCCTCCCGCCAATGC
TGA

# Drug_Target_10_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_10_General_References:
1445347	Arden JR, Nagata O, Shockley MS, Philip M, Lameh J, Sadee W: Mutational analysis of third cytoplasmic loop domains in G-protein coupling of the HM1 muscarinic receptor. Biochem Biophys Res Commun. 1992 Nov 16;188(3):1111-5.
2336407	Chapman CG, Browne MJ: Isolation of the human ml (Hml) muscarinic acetylcholine receptor gene by PCR amplification. Nucleic Acids Res. 1990 Apr 25;18(8):2191.
3443095	Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ: Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9.
3697105	Allard WJ, Sigal IS, Dixon RA: Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor. Nucleic Acids Res. 1987 Dec 23;15(24):10604.

# Drug_Target_10_HGNC_ID:
HGNC:1950

# Drug_Target_10_HPRD_ID:
00338

# Drug_Target_10_ID:
103

# Drug_Target_10_Locus:
11q13

# Drug_Target_10_Molecular_Weight:
51421

# Drug_Target_10_Name:
Muscarinic acetylcholine receptor M1

# Drug_Target_10_Number_of_Residues:
460

# Drug_Target_10_PDB_ID:
Not Available

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_10_Protein_Sequence:
>Muscarinic acetylcholine receptor M1
MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVN
NYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLIS
FDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYI
QFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSS
SERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEV
VIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKE
KKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYAL
CNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover

# Drug_Target_10_SwissProt_ID:
P11229

# Drug_Target_10_SwissProt_Name:
ACM1_HUMAN

# Drug_Target_10_Synonyms:
Not Available

# Drug_Target_10_Theoretical_pI:
9.67

# Drug_Target_10_Transmembrane_Regions:
25-47
62-82
100-121
142-164
187-209
367-387
402-421

# Drug_Target_11_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
2981533	Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
CHRM2

# Drug_Target_11_GenBank_ID_Gene:
M16404

# Drug_Target_11_GenBank_ID_Protein:
177990

# Drug_Target_11_GeneCard_ID:
CHRM2

# Drug_Target_11_Gene_Name:
CHRM2

# Drug_Target_11_Gene_Sequence:
>1401 bp
ATGAATAACTCAACAAACTCCTCTAACAATAGCCTGGCTCTTACAAGTCCTTATAAGACA
TTTGAAGTGGTGTTTATTGTCCTGGTGGCTGGATCCCTCAGTTTGGTGACCATTATCGGG
AACATCCTAGTCATGGTTTCCATTAAAGTCAACCGCCACCTCCAGACCGTCAACAATTAC
TTTTTATTCAGCTTGGCCTGTGCTGACCTTATCATAGGTGTTTTCTCCATGAACTTGTAC
ACCCTCTACACTGTGATTGGTTACTGGCCTTTGGGACCTGTGGTGTGTGACCTTTGGCTA
GCCCTGGACTATGTGGTCAGCAATGCCTCAGTTATGAATCTGCTCATCATCAGCTTTGAC
AGGTACTTCTGTGTCACAAAACCTCTGACCTACCCAGTCAAGCGGACCACAAAAATGGCA
GGTATGATGATTGCAGCTGCCTGGGTCCTCTCTTTCATCCTCTGGGCTCCAGCCATTCTC
TTCTGGCAGTTCATTGTAGGGGTGAGAACTGTGGAGGATGGGGAGTGCTACATTCAGTTT
TTTTCCAATGCTGCTGTCACCTTTGGTACGGCTATTGCAGCCTTCTATTTGCCAGTGATC
ATCATGACTGTGCTATATTGGCACATATCCCGAGCCAGCAAGAGCAGGATAAAGAAGGAC
AAGAAGGAGCCTGTTGCCAACCAAGACCCCGTTTCTCCAAGTCTGGTACAAGGAAGGATA
GTGAAGCCAAACAATAACAACATGCCCAGCAGTGACGATGGCCTGGAGCACAACAAAATC
CAGAATGGCAAAGCCCCCAGGGATCCTGTGACTGAAAACTGTGTTCAGGGAGAGGAGAAG
GAGAGCTCCAATGACTCCACCTCAGTCAGTGCTGTTGCCTCTAATATGAGAGATGATGAA
ATAACCCAGGATGAAAACACAGTTTCCACTTCCCTGGGCCATTCCAAAGATGAGAACTCT
AAGCAAACATGCATCAGAATTGGCACCAAGACCCCAAAAAGTGACTCATGTACCCCAACT
AATACCACCGTGGAGGTAGTGGGGTCTTCAGGTCAGAATGGAGATGAAAAGCAGAATATT
GTAGCCCGCAAGATTGTGAAGATGACTAAGCAGCCTGCAAAAAAGAAGCCTCCTCCTTCC
CGGGAAAAGAAAGTCACCAGGACAATCTTGGCTATTCTGTTGGCTTTCATCATCACTTGG
GCCCCATACAATGTCATGGTGCTCATTAACACCTTTTGTGCACCTTGCATCCCCAACACT
GTGTGGACAATTGGTTACTGGCTTTGTTACATCAACAGCACTATCAACCCTGCCTGCTAT
GCACTTTGCAATGCCACCTTCAAGAAGACCTTTAAACACCTTCTCATGTGTCATTATAAG
AACATAGGCGCTACAAGGTAA

# Drug_Target_11_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_11_General_References:
3037705	Bonner TI, Buckley NJ, Young AC, Brann MR: Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987 Jul 31;237(4814):527-32.
3443095	Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ: Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9.

# Drug_Target_11_HGNC_ID:
HGNC:1951

# Drug_Target_11_HPRD_ID:
00328

# Drug_Target_11_ID:
617

# Drug_Target_11_Locus:
7q31-q35

# Drug_Target_11_Molecular_Weight:
51716

# Drug_Target_11_Name:
Muscarinic acetylcholine receptor M2

# Drug_Target_11_Number_of_Residues:
466

# Drug_Target_11_PDB_ID:
Not Available

# Drug_Target_11_Pathway:
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Flecainide Pathway	SMP00331
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Mexiletine Pathway	SMP00329
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Procainamide (Antiarrhythmic) Pathway	SMP00324
Quinidine Pathway	SMP00323
Tocainide Pathway	SMP00330
Verapamil Pathway	SMP00375

# Drug_Target_11_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_11_Protein_Sequence:
>Muscarinic acetylcholine receptor M2
MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNY
FLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFD
RYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQF
FSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRI
VKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDE
ITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNI
VARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNT
VWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition

# Drug_Target_11_SwissProt_ID:
P08172

# Drug_Target_11_SwissProt_Name:
ACM2_HUMAN

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
9.08

# Drug_Target_11_Transmembrane_Regions:
23-45
60-80
98-119
140-162
185-207
389-409
424-443

# Drug_Target_12_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
2981533	Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
CHRM3

# Drug_Target_12_GenBank_ID_Gene:
X15266

# Drug_Target_12_GenBank_ID_Protein:
32324

# Drug_Target_12_GeneCard_ID:
CHRM3

# Drug_Target_12_Gene_Name:
CHRM3

# Drug_Target_12_Gene_Sequence:
>1773 bp
ATGACCTTGCACAATAACAGTACAACCTCGCCTTTGTTTCCAAACATCAGCTCCTCCTGG
ATACACAGCCCCTCCGATGCAGGGCTGCCCCCGGGAACCGTCACTCATTTCGGCAGCTAC
AATGTTTCTCGAGCAGCTGGCAATTTCTCCTCTCCAGACGGTACCACCGATGACCCTCTG
GGAGGTCATACCGTCTGGCAAGTGGTCTTCATCGCTTTCTTAACGGGCATCCTGGCCTTG
GTGACCATCATCGGCAACATCCTGGTAATTGTGTCATTTAAGGTCAACAAGCAGCTGAAG
ACGGTCAACAACTACTTCCTCTTAAGCCTGGCCTGTGCCGATCTGATTATCGGGGTCATT
TCAATGAATCTGTTTACGACCTACATCATCATGAATCGATGGGCCTTAGGGAACTTGGCC
TGTGACCTCTGGCTTGCCATTGACTACGTAGCCAGCAATGCCTCTGTTATGAATCTTCTG
GTCATCAGCTTTGACAGATACTTTTCCATCACGAGGCCGCTCACGTACCGAGCCAAACGA
ACAACAAAGAGAGCCGGTGTGATGATCGGTCTGGCTTGGGTCATCTCCTTTGTCCTTTGG
GCTCCTGCCATCTTGTTCTGGCAATACTTTGTTGGAAAGAGAACTGTGCCTCCGGGAGAG
TGCTTCATTCAGTTCCTCAGTGAGCCCACCATTACTTTTGGCACAGCCATCGCTGCTTTT
TATATGCCTGTCACCATTATGACTATTTTATACTGGAGGATCTATAAGGAAACTGAAAAG
CGTACCAAAGAGCTTGCTGGCCTGCAAGCCTCTGGGACAGAGGCAGAGACAGAAAACTTT
GTCCACCCCACGGGCAGTTCTCGAAGCTGCAGCAGTTACGAACTTCAACAGCAAAGCATG
AAACGCTCCAACAGGAGGAAGTATGGCCGCTGCCACTTCTGGTTCACAACCAAGAGCTGG
AAACCCAGCTCCGAGCAGATGGACCAAGACCACAGCAGCAGTGACAGTTGGAACAACAAT
GATGCTGCTGCCTCCCTGGAGAACTCCGCCTCCTCCGACGAGGAGGACATTGGCTCCGAG
ACGAGAGCCATCTACTCCATCGTGCTCAAGCTTCCGGGTCACAGCACCATCCTCAACTCC
ACCAAGTTACCCTCATCGGACAACCTGCAGGTGCCTGAGGAGGAGCTGGGGATGGTGGAC
TTGGAGAGGAAAGCCGACAAGCTGCAGGCCCAGAAGAGCGTGGACGATGGAGGCAGTTTT
CCAAAAAGCTTCTCCAAGCTTCCCATCCAGCTAGAGTCAGCCGTGGACACAGCTAAGACT
TCTGACGTCAACTCCTCAGTGGGTAAGAGCACGGCCACTCTACCTCTGTCCTTCAAGGAA
GCCACTCTGGCCAAGAGGTTTGCTCTGAAGACCAGAAGTCAGATCACTAAGCGGAAAAGG
ATGTCCCTGGTCAAGGAGAAGAAAGCGGCCCAGACCCTCAGTGCGATCTTGCTTGCCTTC
ATCATCACTTGGACCCCATACAACATCATGGTTCTGGTGAACACCTTTTGTGACAGCTGC
ATACCCAAAACCTTTTGGAATCTGGGCTACTGGCTGTGCTACATCAACAGCACCGTGAAC
CCCGTGTGCTATGCTCTGTGCAACAAAACATTCAGAACCACTTTCAAGATGCTGCTGCTG
TGCCAGTGTGACAAAAAAAAGAGGCGCAAGCAGCAGTACCAGCAGAGACAGTCGGTCATT
TTTCACAAGCGCGCACCCGAGCAGGCCTTGTAG

# Drug_Target_12_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_12_General_References:
11238933	Speek M: Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol. 2001 Mar;21(6):1973-85.
3272174	Bonner TI, Young AC, Brann MR, Buckley NJ: Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron. 1988 Jul;1(5):403-10.
3443095	Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ: Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9.

# Drug_Target_12_HGNC_ID:
HGNC:1952

# Drug_Target_12_HPRD_ID:
00329

# Drug_Target_12_ID:
51

# Drug_Target_12_Locus:
1q43

# Drug_Target_12_Molecular_Weight:
66129

# Drug_Target_12_Name:
Muscarinic acetylcholine receptor M3

# Drug_Target_12_Number_of_Residues:
590

# Drug_Target_12_PDB_ID:
Not Available

# Drug_Target_12_Pathway:
Cimetidine Pathway	SMP00232
Esomeprazole Pathway	SMP00225
Famotidine Pathway	SMP00231
Lansoprazole Pathway	SMP00227
Nizatidine Pathway	SMP00233
Omeprazole Pathway	SMP00226
Pantoprazole Pathway	SMP00228
Pirenzepine Pathway	SMP00246
Rabeprazole Pathway	SMP00229
Ranitidine Pathway	SMP00230

# Drug_Target_12_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_12_Protein_Sequence:
>Muscarinic acetylcholine receptor M3
MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPL
GGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVI
SMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKR
TTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF
YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSM
KRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSE
TRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSF
PKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKR
MSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVN
PVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover

# Drug_Target_12_SwissProt_ID:
P20309

# Drug_Target_12_SwissProt_Name:
ACM3_HUMAN

# Drug_Target_12_Synonyms:
Not Available

# Drug_Target_12_Theoretical_pI:
9.62

# Drug_Target_12_Transmembrane_Regions:
68-91
105-125
143-164
185-207
230-252
493-513
528-547

# Drug_Target_13_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
2981533	Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
CHRM4

# Drug_Target_13_GenBank_ID_Gene:
M16405

# Drug_Target_13_GenBank_ID_Protein:
61970253

# Drug_Target_13_GeneCard_ID:
CHRM4

# Drug_Target_13_Gene_Name:
CHRM4

# Drug_Target_13_Gene_Sequence:
>1440 bp
ATGGCCAACTTCACACCTGTCAATGGCAGCTCGGGCAATCAGTCCGTGCGCCTGGTCACG
TCATCATCCCACAATCGCTATGAGACGGTGGAAATGGTCTTCATTGCCACAGTGACAGGC
TCCCTGAGCCTGGTGACTGTCGTGGGCAACATCCTGGTGATGCTGTCCATCAAGGTCAAC
AGGCAGCTGCAGACAGTCAACAACTACTTCCTCTTCAGCCTGGCGTGTGCTGATCTCATC
ATAGGCGCCTTCTCCATGAACCTCTACACCGTGTACATCATCAAGGGCTACTGGCCCCTG
GGCGCCGTGGTCTGCGACCTGTGGCTGGCCCTGGACTACGTGGTGAGCAACGCCTCCGTC
ATGAACCTTCTCATCATCAGCTTTGACCGCTACTTCTGCGTCACCAAGCCTCTCACCTAC
CCTGCCCGGCGCACCACCAAGATGGCAGGCCTCATGATTGCTGCTGCCTGGGTACTGTCC
TTCGTGCTCTGGGCGCCTGCCATCTTGTTCTGGCAGTTTGTGGTGGGTAAGCGGACGGTG
CCCGACAACCAGTGCTTCATCCAGTTCCTGTCCAACCCAGCAGTGACCTTTGGCACAGCC
ATTGCTGCCTTCTACCTGCCTGTGGTCATCATGACGGTGCTGTACATCCACATCTCCCTG
GCCAGTCGCAGCCGAGTCCACAAGCACCGGCCCGAGGGCCCGAAGGAGAAGAAAGCCAAG
ACGCTGGCCTTCCTCAAGAGCCCACTAATGAAGCAGAGCGTCAAGAAGCCCCCGCCCGGG
GAGGCCGCCCGGGAGGAGCTGCGCAATGGCAAGCTGGAGGAGGCCCCCCCGCCAGCGCTG
CCACCGCCACCGCGCCCCGTGGCTGATAAGGACACTTCCAATGAGTCCAGCTCAGGCAGT
GCCACCCAGAACACCAAGGAACGCCCAGCCACAGAGCTGTCCACCACAGAGGCCACCACG
CCCGCCATGCCCGCCCCTCCCCTGCAGCCGCGGGCCCTCAACCCAGCCTCCAGATGGTCC
AAGATCCAGATTGTGACGAAGCAGACAGGCAATGAGTGTGTGACAGCCATTGAGATTGTG
CCTGCCACGCCGGCTGGCATGCGCCCTGCGGCCAACGTGGCCCGCAAGTTCGCCAGCATC
GCTCGCAACCAGGTGCGCAAGAAGCGGCAGATGGCGGCCCGGGAGCGCAAAGTGACACGA
ACGATCTTTGCCATTCTGCTAGCCTTCATCCTCACCTGGACGCCCTACAACGTCATGGTC
CTGGTGAACACCTTCTGCCAGAGCTGCATCCCTGACACGGTGTGGTCCATTGGCTACTGG
CTCTGCTACGTCAACAGCACCATCAACCCTGCCTGCTATGCTCTGTGCAACGCCACCTTT
AAAAAGACCTTCCGGCACCTGCTGCTGTGCCAGTATCGGAACATCGGCACTGCCAGGTAG

# Drug_Target_13_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_13_General_References:
3037705	Bonner TI, Buckley NJ, Young AC, Brann MR: Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987 Jul 31;237(4814):527-32.
3272174	Bonner TI, Young AC, Brann MR, Buckley NJ: Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron. 1988 Jul;1(5):403-10.
3443095	Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ: Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9.

# Drug_Target_13_HGNC_ID:
HGNC:1953

# Drug_Target_13_HPRD_ID:
00330

# Drug_Target_13_ID:
450

# Drug_Target_13_Locus:
11p12-p11.2

# Drug_Target_13_Molecular_Weight:
53050

# Drug_Target_13_Name:
Muscarinic acetylcholine receptor M4

# Drug_Target_13_Number_of_Residues:
479

# Drug_Target_13_PDB_ID:
Not Available

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_13_Protein_Sequence:
>Muscarinic acetylcholine receptor M4
MANFTPVNGSSGNQSVRLVTSSSHNRYETVEMVFIATVTGSLSLVTVVGNILVMLSIKVN
RQLQTVNNYFLFSLACADLIIGAFSMNLYTVYIIKGYWPLGAVVCDLWLALDYVVSNASV
MNLLIISFDRYFCVTKPLTYPARRTTKMAGLMIAAAWVLSFVLWAPAILFWQFVVGKRTV
PDNQCFIQFLSNPAVTFGTAIAAFYLPVVIMTVLYIHISLASRSRVHKHRPEGPKEKKAK
TLAFLKSPLMKQSVKKPPPGEAAREELRNGKLEEAPPPALPPPPRPVADKDTSNESSSGS
ATQNTKERPATELSTTEATTPAMPAPPLQPRALNPASRWSKIQIVTKQTGNECVTAIEIV
PATPAGMRPAANVARKFASIARNQVRKKRQMAARERKVTRTIFAILLAFILTWTPYNVMV
LVNTFCQSCIPDTVWSIGYWLCYVNSTINPACYALCNATFKKTFRHLLLCQYRNIGTAR

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase

# Drug_Target_13_SwissProt_ID:
P08173

# Drug_Target_13_SwissProt_Name:
ACM4_HUMAN

# Drug_Target_13_Synonyms:
Not Available

# Drug_Target_13_Theoretical_pI:
10.34

# Drug_Target_13_Transmembrane_Regions:
32-54
69-89
107-128
149-171
194-216
402-422
437-456

# Drug_Target_14_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
2981533	Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
CHRM5

# Drug_Target_14_GenBank_ID_Gene:
M80333

# Drug_Target_14_GenBank_ID_Protein:
177988

# Drug_Target_14_GeneCard_ID:
CHRM5

# Drug_Target_14_Gene_Name:
CHRM5

# Drug_Target_14_Gene_Sequence:
>1599 bp
ATGGAAGGGGATTCTTACCACAATGCAACCACCGTCAATGGCACCCCAGTAAATCACCAG
CCTTTGGAACGCCACAGGTTGTGGGAAGTCATCACCATTGCAGCTGTGACTGCTGTGGTA
AGCCTGATCACCATTGTGGGCAATGTCTTGGTCATGATCTCCTTCAAAGTCAACAGCCAG
CTCAAGACAGTTAACAACTATTACCTGCTCAGCTTAGCCTGTGCAGATCTCATCATTGGA
ATCTTCTCCATGAACCTCTACACCACCTACATCCTCATGGGACGCTGGGCTCTCGGGAGT
CTGGCTTGTGACCTTTGGCTTGCACTGGACTACGTGGCCAGCAACGCTTCTGTCATGAAC
CTTCTGGTGATCAGTTTTGACCGTTACTTTTCCATCACAAGACCCTTGACATATCGGGCC
AAGCGTACTCCGAAAAGGGCTGGCATCATGATTGGCTTGGCCTGGCTGATCTCCTTCATC
CTCTGGGCCCCAGCAATCCTCTGCTGGCAGTACTTGGTTGGGAAGCGGACAGTTCCACTG
GATGAGTGCCAGATCCAGTTTCTCTCTGAGCCCACCATCACTTTTGGCACTGCCATTGCT
GCCTTCTACATCCCTGTTTCTGTCATGACCATCCTCTACTGTCGAATCTACCGGGAAACA
GAGAAGCGAACCAAGGACCTGGCTGACCTCCAGGGTTCTGACTCTGTGACCAAAGCTGAG
AAGAGAAAGCCAGCTCATAGGGCTCTGTTCAGATCCTGCTTGCGCTGTCCTCGACCCACC
CTGGCCCAGCGGGAAAGGAACCAGGCCTCCTGGTCATCCTCCCGCAGGAGCACCTCCACC
ACTGGGAAGCCATCCCAAGCCACTGGCCCAAGCGCCAATTGGGCCAAAGCTGAGCAGCTC
ACCACCTGTAGCAGCTACCCTTCCTCAGAGGATGAGGACAAGCCCGCCACTGACCCTGTC
CTCCAAGTGGTCTACAAGAGTCAGGGTAAGGAAAGCCCAGGGGAAGAATTCAGTGCTGAA
GAGACTGAGGAAACTTTTGTGAAAGCTGAAACTGAAAAAAGTGACTATGACACCCCAAAC
TACCTTCTGTCTCCAGCAGCTGCTCATAGACCCAAGAGTCAGAAATGTGTGGCCTATAAG
TTCCGATTGGTGGTAAAAGCTGACGGGAACCAGGAGACCAACAATGGCTGTCACAAGGTG
AAAATCATGCCCTGCCCCTTCCCAGTGGCCAAGGAACCTTCAACGAAAGGCCTCAATCCC
AACCCCAGCCATCAAATGACCAAACGAAAGAGAGTGGTCCTAGTCAAAGAGAGGAAAGCA
GCCCAGACACTGAGTGCCATTCTCCTGGCCTTCATCATCACATGGACCCCGTATAACATC
ATGGTCCTGGTTTCTACCTTCTGTGACAAGTGTGTCCCAGTCACCCTGTGGCACTTGGGC
TATTGGTTGTGCTATGTCAATAGCACTGTCAACCCCATCTGCTATGCCCTCTGCAACAGA
ACCTTCAGGAAGACCTTTAAGATGCTGCTTCTCTGCCGATGGAAAAAGAAAAAAGTGGAA
GAGAAGTTGTACTGGCAGGGGAACAGCAAGCTACCCTGA

# Drug_Target_14_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_14_General_References:
3272174	Bonner TI, Young AC, Brann MR, Buckley NJ: Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron. 1988 Jul;1(5):403-10.

# Drug_Target_14_HGNC_ID:
HGNC:1954

# Drug_Target_14_HPRD_ID:
00331

# Drug_Target_14_ID:
274

# Drug_Target_14_Locus:
15q26

# Drug_Target_14_Molecular_Weight:
60074

# Drug_Target_14_Name:
Muscarinic acetylcholine receptor M5

# Drug_Target_14_Number_of_Residues:
532

# Drug_Target_14_PDB_ID:
Not Available

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_14_Protein_Sequence:
>Muscarinic acetylcholine receptor M5
MEGDSYHNATTVNGTPVNHQPLERHRLWEVITIAAVTAVVSLITIVGNVLVMISFKVNSQ
LKTVNNYYLLSLACADLIIGIFSMNLYTTYILMGRWALGSLACDLWLALDYVASNASVMN
LLVISFDRYFSITRPLTYRAKRTPKRAGIMIGLAWLISFILWAPAILCWQYLVGKRTVPL
DECQIQFLSEPTITFGTAIAAFYIPVSVMTILYCRIYRETEKRTKDLADLQGSDSVTKAE
KRKPAHRALFRSCLRCPRPTLAQRERNQASWSSSRRSTSTTGKPSQATGPSANWAKAEQL
TTCSSYPSSEDEDKPATDPVLQVVYKSQGKESPGEEFSAEETEETFVKAETEKSDYDTPN
YLLSPAAAHRPKSQKCVAYKFRLVVKADGNQETNNGCHKVKIMPCPFPVAKEPSTKGLNP
NPSHQMTKRKRVVLVKERKAAQTLSAILLAFIITWTPYNIMVLVSTFCDKCVPVTLWHLG
YWLCYVNSTVNPICYALCNRTFRKTFKMLLLCRWKKKKVEEKLYWQGNSKLP

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover

# Drug_Target_14_SwissProt_ID:
P08912

# Drug_Target_14_SwissProt_Name:
ACM5_HUMAN

# Drug_Target_14_Synonyms:
Not Available

# Drug_Target_14_Theoretical_pI:
9.64

# Drug_Target_14_Transmembrane_Regions:
30-53
67-87
105-126
147-169
192-214
444-464
479-498

# Drug_Target_15_Cellular_Location:
Not Available

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
6865927	Thayer SA, Fairhurst AS: The interaction of dihydropyridine calcium channel blockers with calmodulin and calmodulin inhibitors. Mol Pharmacol. 1983 Jul;24(1):6-9.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
CALM1

# Drug_Target_15_GenBank_ID_Gene:
J04046

# Drug_Target_15_GenBank_ID_Protein:
179888

# Drug_Target_15_GeneCard_ID:
CALM1

# Drug_Target_15_Gene_Name:
CALM1

# Drug_Target_15_Gene_Sequence:
>450 bp
ATGGCTGACCAGCTGACTGAGGAGCAGATTGCAGAGTTCAAGGAGGCCTTCTCCCTCTTT
GACAAGGATGGAGATGGCACTATCACCACCAAGGAGTTGGGGACAGTGATGAGATCCCTG
GGACAGAACCCCACTGAAGCAGAGCTGCAGGATATGATCAATGAGGTGGATGCAGATGGG
AACGGGACCATTGACTTCCCGGAGTTCCTGACCATGATGGCCAGAAAGATGAAGGACACA
GACAGTGAGGAGGAGATCCGAGAGGCGTTCCGTGTCTTTGACAAGGATGGGAATGGCTAC
ATCAGCGCCGCAGAGCTGCGTCACGTAATGACGAACCTGGGGGAGAAGCTGACCGATGAG
GAGGTGGATGAGATGATCAGGGAGGCTGACATCGATGGAGATGGCCAGGTCAATTATGAA
GAGTTTGTACAGATGATGACTGCAAAGTGA

# Drug_Target_15_General_Function:
Involved in calcium ion binding

# Drug_Target_15_General_References:
11807546	Drum CL, Yan SZ, Bard J, Shen YQ, Lu D, Soelaiman S, Grabarek Z, Bohm A, Tang WJ: Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature. 2002 Jan 24;415(6870):396-402.
12508121	Heilig R, Eckenberg R, Petit JL, Fonknechten N, Da Silva C, Cattolico L, Levy M, Barbe V, de Berardinis V, Ureta-Vidal A, Pelletier E, Vico V, Anthouard V, Rowen L, Madan A, Qin S, Sun H, Du H, Pepin K, Artiguenave F, Robert C, Cruaud C, Bruls T, Jaillon O, Friedlander L, Samson G, Brottier P, Cure S, Segurens B, Aniere F, Samain S, Crespeau H, Abbasi N, Aiach N, Boscus D, Dickhoff R, Dors M, Dubois I, Friedman C, Gouyvenoux M, James R, Madan A, Mairey-Estrada B, Mangenot S, Martins N, Menard M, Oztas S, Ratcliffe A, Shaffer T, Trask B, Vacherie B, Bellemere C, Belser C, Besnard-Gonnet M, Bartol-Mavel D, Boutard M, Briez-Silla S, Combette S, Dufosse-Laurent V, Ferron C, Lechaplais C, Louesse C, Muselet D, Magdelenat G, Pateau E, Petit E, Sirvain-Trukniewicz P, Trybou A, Vega-Czarny N, Bataille E, Bluet E, Bordelais I, Dubois M, Dumont C, Guerin T, Haffray S, Hammadi R, Muanga J, Pellouin V, Robert D, Wunderle E, Gauguet G, Roy A, Sainte-Marthe L, Verdier J, Verdier-Discala C, Hillier L, Fulton L, McPherson J, Matsuda F, Wilson R, Scarpelli C, Gyapay G, Wincker P, Saurin W, Quetier F, Waterston R, Hood L, Weissenbach J: The DNA sequence and analysis of human chromosome 14. Nature. 2003 Feb 6;421(6923):601-7. Epub 2003 Jan 1.
2223880	Koller M, Schnyder B, Strehler EE: Structural organization of the human CaMIII calmodulin gene. Biochim Biophys Acta. 1990 Oct 23;1087(2):180-9.
2445749	SenGupta B, Friedberg F, Detera-Wadleigh SD: Molecular analysis of human and rat calmodulin complementary DNA clones. Evidence for additional active genes in these species. J Biol Chem. 1987 Dec 5;262(34):16663-70.
3182832	Fischer R, Koller M, Flura M, Mathews S, Strehler-Page MA, Krebs J, Penniston JT, Carafoli E, Strehler EE: Multiple divergent mRNAs code for a single human calmodulin. J Biol Chem. 1988 Nov 15;263(32):17055-62.
6385987	Wawrzynczak EJ, Perham RN: Isolation and nucleotide sequence of a cDNA encoding human calmodulin. Biochem Int. 1984 Aug;9(2):177-85.
7093203	Sasagawa T, Ericsson LH, Walsh KA, Schreiber WE, Fischer EH, Titani K: Complete amino acid sequence of human brain calmodulin. Biochemistry. 1982 May 11;21(10):2565-9.
7925473	Rhyner JA, Ottiger M, Wicki R, Greenwood TM, Strehler EE: Structure of the human CALM1 calmodulin gene and identification of two CALM1-related pseudogenes CALM1P1 and CALM1P2. Eur J Biochem. 1994 Oct 1;225(1):71-82.
9681195	Toutenhoofd SL, Foletti D, Wicki R, Rhyner JA, Garcia F, Tolon R, Strehler EE: Characterization of the human CALM2 calmodulin gene and comparison of the transcriptional activity of CALM1, CALM2 and CALM3. Cell Calcium. 1998 May;23(5):323-38.

# Drug_Target_15_HGNC_ID:
HGNC:1442

# Drug_Target_15_HPRD_ID:
00243

# Drug_Target_15_ID:
465

# Drug_Target_15_Locus:
14q24-q31

# Drug_Target_15_Molecular_Weight:
16707

# Drug_Target_15_Name:
Calmodulin

# Drug_Target_15_Number_of_Residues:
148

# Drug_Target_15_PDB_ID:
1IQ5

# Drug_Target_15_Pathway:
Acebutolol Pathway	SMP00296
Alprenolol Pathway	SMP00297
Amlodipine Pathway	SMP00376
Atenolol Pathway	SMP00298
Benazepril Pathway	SMP00145
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Captopril Pathway	SMP00146
Carvedilol Pathway	SMP00367
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Enalapril Pathway	SMP00148
Esmolol Pathway	SMP00301
Felodipine Pathway	SMP00377
Fosinopril Pathway	SMP00149
Isradipine Pathway	SMP00378
Labetalol Pathway	SMP00368
Lisinopril Pathway	SMP00150
Metoprolol Pathway	SMP00302
Moexipril Pathway	SMP00151
Nadolol Pathway	SMP00303
Nebivolol Pathway	SMP00366
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Oxprenolol Pathway	SMP00304
Penbutolol Pathway	SMP00305
Perindopril Pathway	SMP00152
Pindolol Pathway	SMP00306
Propranolol Pathway	SMP00307
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_15_Pfam_Domain_Function:
PF00036	efhand

# Drug_Target_15_Protein_Sequence:
>Calmodulin
ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGN
GTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEE
VDEMIREADIDGDGQVNYEEFVQMMTAK

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Calmodulin mediates the control of a large number of enzymes and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases

# Drug_Target_15_SwissProt_ID:
P62158

# Drug_Target_15_SwissProt_Name:
CALM_HUMAN

# Drug_Target_15_Synonyms:
CaM

# Drug_Target_15_Theoretical_pI:
3.84

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CACNA1C

# Drug_Target_1_GenBank_ID_Gene:
M92270

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
CACNA1C

# Drug_Target_1_Gene_Name:
CACNA1C

# Drug_Target_1_Gene_Sequence:
>6666 bp
ATGGTCAATGAGAATACGAGGATGTACATTCCAGAGGAAAACCACCAAGGTTCCAACTAT
GGGAGCCCACGCCCCGCCCATGCCAACATGAATGCCAATGCGGCAGCGGGGCTGGCCCCT
GAGCACATCCCCACCCCGGGGGCTGCCCTGTCGTGGCAGGCGGCCATCGACGCAGCCCGG
CAGGCTAAGCTGATGGGCAGCGCTGGCAATGCGACCATCTCCACAGTCAGCTCCACGCAG
CGGAAGCGGCAGCAATATGGGAAACCCAAGAAGCAGGGCAGCACCACGGCCACACGCCCG
CCCCGAGCCCTGCTCTGCCTGACCCTGAAGAACCCCATCCGGAGGGCCTGCATCAGCATT
GTCGAATGGAAACCATTTGAAATAATTATTTTACTGACTATTTTTGCCAATTGTGTGGCC
TTAGCGATCTATATTCCCTTTCCAGAAGATGATTCCAACGCCACCAATTCCAACCTGGAA
CGAGTGGAATATCTCTTTCTCATAATTTTTACGGTGGAAGCGTTTTTAAAAGTAATCGCC
TATGGACTCCTCTTTCACCCCAATGCCTACCTCCGCAACGGCTGGAACCTACTAGATTTT
ATAATTGTGGTTGTGGGGCTTTTTAGTGCAATTTTAGAACAAGCAACCAAAGCAGATGGG
GCAAACGCTCTCGGAGGGAAAGGGGCCGGATTTGATGTGAAGGCGCTGAGGGCCTTCCGC
GTGCTGCGCCCCCTGCGGCTGGTGTCCGGAGTCCCAAGTCTCCAGGTGGTCCTGAATTCC
ATCATCAAGGCCATGGTCCCCCTGCTGCACATCGCCCTGCTTGTGCTGTTTGTCATCATC
ATCTACGCCATCATCGGCTTGGAGCTCTTCATGGGGAAGATGCACAAGACCTGCTACAAC
CAGGAGGGCATAGCAGATGTTCCAGCAGAAGATGACCCTTCCCCTTGTGCGCTGGAAACG
GGCCACGGGCGGCAGTGCCAGAACGGCACGGTGTGCAAGCCCGGCTGGGATGGTCCCAAG
CACGGCATCACCAACTTTGACAACTTTGCCTTCGCCATGCTCACGGTGTTCCAGTGCATC
ACCATGGAGGGCTGGACGGACGTGCTGTACTGGGTCAATGATGCCGTAGGAAGGGACTGG
CCCTGGATCTATTTTGTTACACTAATCATCATAGGGTCATTTTTTGTACTTAACTTGGTT
CTCGGTGTGCTTAGCGGAGAGTTTTCCAAAGAGAGGGAGAAGGCCAAGGCCCGGGGAGAT
TTCCAGAAGCTGCGGGAGAAGCAGCAGCTAGAAGAGGATCTCAAAGGCTACCTGGATTGG
ATCACTCAGGCCGAAGACATCGATCCTGAGAATGAGGACGAAGGCATGGATGAGGAGAAG
CCCCGAAACATGAGCATGCCCACCAGTGAGACCGAGTCCGTCAACACCGAAAACGTGGCT
GGAGGTGACATCGAGGGAGAAAACTGCGGGGCCAGGCTGGCCCACCGGATCTCCAAGTCA
AAGTTCAGCCGCTACTGGCGCCGGTGGAATCGGTTCTGCAGAAGGAAGTGCCGCGCCGCA
GTCAAGTCTAATGTCTTCTACTGGCTGGTGATTTTCCTGGTGTTCCTCAACACGCTCACC
ATTGCCTCTGAGCACTACAACCAGCCCAACTGGCTCACAGAAGTCCAAGACACGGCAAAC
AAGGCCCTGCTGGCCCTGTTCACGGCAGAGATGCTCCTGAAGATGTACAGCCTGGGCCTG
CAGGCCTACTTCGTGTCCCTCTTCAACCGCTTTGACTGCTTCGTCGTGTGTGGCGGCATC
CTGGAGACCATCCTGGTGGAGACCAAGATCATGTCCCCACTGGGCATCTCCGTGCTCAGA
TGCGTCCGGCTGCTGAGGATTTTCAAGATCACGAGGTACTGGAACTCCTTGAGCAACCTG
GTGGCATCCTTGCTGAACTCTGTGCGCTCCATCGCCTCCCTGCTCCTTCTCCTCTTCCTC
TTCATCATCATCTTCTCCCTCCTGGGGATGCAGCTCTTTGGAGGAAAGTTCAACTTTGAT
GAGATGCAGACCCGGAGGAGCACATTCGATAACTTCCCCCAGTCCCTCCTCACTGTGTTT
CAGATCCTGACCGGGGAGGACTGGAATTCGGTGATGTATGATGGGATCATGGCTTATGGC
GGCCCCTCTTTTCCAGGGATGTTAGTCTGTATTTACTTCATCATCCTCTTCATCTGTGGA
AACTATATCCTACTGAATGTGTTCTTGGCCATTGCTGTGGACAACCTGGCTGATGCTGAG
AGCCTCACATCTGCCCAAAAGGAGGAGGAAGAGGAGAAGGAGAGAAAGAAGCTGGCCAGG
ACTGCCAGCCCAGAGAAGAAACAAGAGTTGGTGGAGAAGCCGGCAGTGGGGGAATCCAAG
GAGGAGAAGATTGAGCTGAAATCCATCACGGCTGACGGAGAGTCTCCACCCGCCACCAAG
ATCAACATGGATGACCTCCAGCCCAATGAAAATGAGGATAAGAGCCCCTACCCCAACCCA
GAAACTACAGGAGAAGAGGATGAGGAGGAGCCAGAGATGCCTGTCGGCCCTCGCCCACGA
CCACTCTCTGAGCTTCACCTTAAGGAAAAGGCAGTGCCCATGCCAGAAGCCAGCGCGTTT
TTCATCTTCAGCTCTAACAACAGGTTTCGCCTCCAGTGCCACCGCATTGTCAATGACACG
ATCTTCACCAACCTGATCCTCTTCTTCATTCTGCTCAGCAGCATTTCCCTGGCTGCTGAG
GACCCGGTCCAGCACACCTCCTTCAGGAACCATATTCTGTTTTATTTTGATATTGTTTTT
ACCACCATTTTCACCATTGAAATTGCTCTGAAGATCCTAGGCAATGCAGACTATGTCTTC
ACTAGTATCTTTACATTAGAAATTATCCTTAAGATGACTGCTTATGGGGCTTTCTTGCAC
AAGGGTTCTTTCTGCCGGAACTACTTCAACATCCTGGACCTGCTGGTGGTCAGCGTGTCC
CTCATCTCCTTTGGCATCCAGTCCAGTGCAATCAATGTCGTGAAGATCTTGCGAGTCCTG
CGAGTACTCAGGCCCCTGAGGGCCATCAACAGGGCCAAGGGGCTAAAGCATGTGGTTCAG
TGTGTGTTTGTCGCCATCCGGACCATCGGGAACATCGTGATTGTCACCACCCTGCTGCAG
TTCATGTTTGCCTGCATCGGGGTCCAGCTCTTCAAGGGAAAGCTGTACACCTGTTCAGAC
AGTTCCAAGCAGACAGAGGCGGAATGCAAGGGCAACTACATCACGTACAAAGACGGGGAG
GTTGACCACCCCATCATCCAACCCCGCAGCTGGGAGAACAGCAAGTTTGACTTTGACAAT
GTTCTGGCAGCCATGATGGCCCTCTTCACCGTCTCCACCTTCGAAGGGTGGCCAGAGCTG
CTGTACCGCTCCATCGACTCCCACACGGAAGACAAGGGCCCCATCTACAACTACCGTGTG
GAGATCTCCATCTTCTTCATCATCTACATCATCATCATCGCCTTCTTCATGATGAACATC
TTCGTGGGCTTCGTCATCGTCACCTTTCAGGAGCAGGGGGAGCAGGAGTACAAGAACTGT
GAGCTGGACAAGAACCAGCGACAGTGCGTGGAATACGCCCTCAAGGCCCGGCCCCTGCGG
AGGTACATCCCCAAGAACCAGCACCAGTACAAAGTGTGGTACGTGGTCAACTCCACCTAC
TTCGAGTACCTGATGTTCGTCCTCATCCTGCTCAACACCATCTGCCTGGCCATGCAGCAC
TACGGCCAGAGCTGCCTGTTCAAAATCGCCATGAACATCCTCAACATGCTCTTCACTGGC
CTCTTCACCGTGGAGATGATCCTGAAGCTCATTGCCTTCAAACCCAAGGGTTACTTTAGT
GATCCCTGGAATGTTTTTGACTTCCTCATCGTAATTGGCAGCATAATTGACGTCATTCTC
AGTGAGACTAATCACTATTTCTGTGATGCATGGAATACATTTGACGCCTTGATTGTTGTG
GGTAGCATTGTTGATATAGCAATCACCGAGGTAAACCCAGCTGAACATACCCAATGCTCT
CCCTCTATGAACGCAGAGGAAAACTCCCGCATCTCCATCACCTTCTTCCGCCTGTTCCGG
GTCATGCGTCTGGTGAAGCTGCTGAGCCGTGGGGAGGGCATCCGGACGCTGCTGTGGACC
TTCATCAAGTCCTTCCAGGCCCTGCCCTATGTGGCCCTCCTGATCGTGATGCTGTTCTTC
ATCTACGCGGTGATCGGGATGCAGGTGTTTGGGAAAATTGCCCTGAATGATACCACAGAG
ATCAACCGGAACAACAACTTTCAGACCTTCCCCCAGGCCGTGCTGCTCCTCTTCAGGTGT
GCCACCGGGGAGGCCTGGCAGGACATCATGCTGGCCTGCATGCCAGGCAAGAAGTGTGCC
CCAGAGTCCGAGCCCAGCAACAGCACGGAGGGTGAAACACCCTGTGGTAGCAGCTTTGCT
GTCTTCTACTTCATCAGCTTCTACATGCTCTGTGCCTTCCTGATCATCAACCTCTTTGTA
GCTGTCATCATGGACAACTTTGACTACCTGACAAGGGACTGGTCCATCCTTGGTCCCCAC
CACCTGGATGAGTTTAAAAGAATCTGGGCAGAGTATGACCCTGAAGCCAAGGGTCGTATC
AAACACCTGGATGTGGTGACCCTCCTCCGGCGGATTCAGCCGCCACTAGGTTTTGGGAAG
CTGTGCCCTCACCGCGTGGCTTGCAAACGCCTGGTCTCCATGAACATGCCTCTGAACAGC
GACGGGACAGTCATGTTCAATGCCACCCTGTTTGCCCTGGTCAGGACGGCCCTGAGGATC
AAAACAGAAGGGAACCTAGAACAAGCCAATGAGGAGCTGCGGGCGATCATCAAGAAGATC
TGGAAGCGGACCAGCATGAAGCTGCTGGACCAGGTGGTGCCCCCTGCAGGTGATGATGAG
GTCACCGTTGGCAAGTTCTACGCCACGTTCCTGATCCAGGAGTACTTCCGGAAGTTCAAG
AAGCGCAAAGAGCAGGGCCTTGTGGGCAAGCCCTCCCAGAGGAACGCGCTGTCTCTGCAG
GCTGGCTTGCGCACACTGCATGACATCGGGCCTGAGATCCGACGGGCCATCTCTGGAGAT
CTCACCGCTGAGGAGGAGCTGGACAAGGCCATGAAGGAGGCTGTGTCCGCTGCTTCTGAA
GATGACATCTTCAGGAGGGCCGGTGGCCTGTTCGGCAACCACGTCAGCTACTACCAAAGC
GACGGCCGGAGCGCCTTCCCCCAGACCTTCACCACTCAGCGCCCGCTGCACATCAACAAG
GCGGGCAGCAGCCAGGGCGACACTGAGTCGCCATCCCACGAGAAGCTGGTGGACTCCACC
TTCACCCCGAGCAGCTACTCGTCCACCGGCTCCAACGCCAACATCAACAACGCCAACAAC
ACCGCCCTGGGTCGCCTCCCTCGCCCCGCCGGCTACCCCAGCACGGTCAGCACTGTGGAG
GGCCACGGGCCCCCCTTGTCCCCTGCCATCCGGGTGCAGGAGGTGGCGTGGAAGCTCAGC
TCCAACAGGGAAAGGCACGTTCCGGTGTGTGAGGATCTGGAGCTCAGGAGGGATTCAGGC
TCAGCAGGGACTCAGGCTCACTGCCTTCTGCTCAGGAGAGCAAACCCCTCTAGGTGCCAC
TCCCGGGAGAGCCAGGCAGCCATGGCGGGTCAGGAGGAGACGTCTCAGGATGAGACCTAT
GAAGTGAAGATGAACCATGACACGGAGGCCTGCAGTGAGCCCAGCCTGCTCTCCACAGAG
ATGCTCTCCTACCAGGATGACGAAAATCGGCAACTGACGCTCCCAGAGGAGGACAAGAGG
GACATCCGGCAATCTCCGAAGAGGGGTTTCCTCCGCTCTGCCTCACTAGGTCGAAGGGCC
TCCTTCCACCTGGAATGTCTGAAGCGACAGAAGGACCGAGGGGGAGACATCTCTCAGAAG
ACAGTCCTGCCCTTGCATCTGGTTCATCATCAGGCATTGGCAGTGGCAGGCCTGAGCCCC
CTCCTCCAGAGAAGCCATTCCCCTGCCTCATTCCCTAGGCCTTTTGCCACCCCACCAGCC
ACACCTGGCAGCCGAGGCTGGCCCCCACAGCCCGTCCCCACCCTGCGGCTTGAGGGGGTC
GAGTCCAGTGAGAAACTCAACAGCAGCTTCCCATCCATCCACTGCGGCTCCTGGGCTGAG
ACCACCCCCGGTGGCGGGGGCAGCAGCGCCGCCCGGAGAGTCCGGCCCGTCTCCCTCATG
GTGCCCAGCCAGGCTGGGGCCCCAGGGAGGCAGTTCCACGGCAGTGCCAGCAGCCTGGTG
GAAGCGGTCTTGATTTCAGAAGGACTGGGGCAGTTTGCTCAAGATCCCAAGTTCATCGAG
GTCACCACCCAGGAGCTGGCCGACGCCTGCGACATGACCATAGAGGAGATGGAGAGCGCG
GCCGACAACATCCTCAGCGGGGGCGCCCCACAGAGCCCCAATGGCGCCCTCTTACCCTTT
GTGAACTGCAGGGACGCGGGGCAGGACCGAGCCGGGGGCGAAGAGGACGCGGGCTGTGTG
CGCGCGCGGGGTGGACCGAGTGAGGAGGAGCTCCAGGACAGCAGGGTCTACGTCAGCAGC
CTGTAG

# Drug_Target_1_General_Function:
Involved in voltage-gated calcium channel activity

# Drug_Target_1_General_References:
1316612	Soldatov NM: Molecular diversity of L-type Ca2+ channel transcripts in human fibroblasts. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4628-32.
1335957	Sun W, McPherson JD, Hoang DQ, Wasmuth JJ, Evans GA, Montal M: Mapping of a human brain voltage-gated calcium channel to human chromosome 12p13-pter. Genomics. 1992 Dec;14(4):1092-4.
1653763	Powers PA, Gregg RG, Lalley PA, Liao M, Hogan K: Assignment of the human gene for the alpha 1 subunit of the cardiac DHP-sensitive Ca2+ channel (CCHL1A1) to chromosome 12p12-pter. Genomics. 1991 Jul;10(3):835-9.
2173707	Perez-Reyes E, Wei XY, Castellano A, Birnbaumer L: Molecular diversity of L-type calcium channels. Evidence for alternative splicing of the transcripts of three non-allelic genes. J Biol Chem. 1990 Nov 25;265(33):20430-6.
7737988	Soldatov NM, Bouron A, Reuter H: Different voltage-dependent inhibition by dihydropyridines of human Ca2+ channel splice variants. J Biol Chem. 1995 May 5;270(18):10540-3.
7959794	Soldatov NM: Genomic structure of human L-type Ca2+ channel. Genomics. 1994 Jul 1;22(1):77-87.
8099908	Tang S, Mikala G, Bahinski A, Yatani A, Varadi G, Schwartz A: Molecular localization of ion selectivity sites within the pore of a human L-type cardiac calcium channel. J Biol Chem. 1993 Jun 25;268(18):13026-9.
8392192	Schultz D, Mikala G, Yatani A, Engle DB, Iles DE, Segers B, Sinke RJ, Weghuis DO, Klockner U, Wakamori M, et al.: Cloning, chromosomal localization, and functional expression of the alpha 1 subunit of the L-type voltage-dependent calcium channel from normal human heart. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6228-32.
9013606	Soldatov NM, Zuhlke RD, Bouron A, Reuter H: Molecular structures involved in L-type calcium channel inactivation. Role of the carboxyl-terminal region encoded by exons 40-42 in alpha1C subunit in the kinetics and Ca2+ dependence of inactivation. J Biol Chem. 1997 Feb 7;272(6):3560-6.
9087614	Klockner U, Mikala G, Eisfeld J, Iles DE, Strobeck M, Mershon JL, Schwartz A, Varadi G: Properties of three COOH-terminal splice variants of a human cardiac L-type Ca2+-channel alpha1-subunit. Am J Physiol. 1997 Mar;272(3 Pt 2):H1372-81.

# Drug_Target_1_HGNC_ID:
HGNC:1390

# Drug_Target_1_HPRD_ID:
00246

# Drug_Target_1_ID:
478

# Drug_Target_1_Locus:
12p13.3

# Drug_Target_1_Molecular_Weight:
248890

# Drug_Target_1_Name:
Voltage-dependent L-type calcium channel subunit alpha-1C

# Drug_Target_1_Number_of_Residues:
2221

# Drug_Target_1_PDB_ID:
1VYT

# Drug_Target_1_Pathway:
Acebutolol Pathway	SMP00296
Alprenolol Pathway	SMP00297
Amlodipine Pathway	SMP00376
Atenolol Pathway	SMP00298
Benazepril Pathway	SMP00145
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Captopril Pathway	SMP00146
Carvedilol Pathway	SMP00367
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Esmolol Pathway	SMP00301
Felodipine Pathway	SMP00377
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Isradipine Pathway	SMP00378
Labetalol Pathway	SMP00368
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lisinopril Pathway	SMP00150
Metoprolol Pathway	SMP00302
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Nadolol Pathway	SMP00303
Nebivolol Pathway	SMP00366
Nicotine Pathway	SMP00431
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Oxprenolol Pathway	SMP00304
Penbutolol Pathway	SMP00305
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Pindolol Pathway	SMP00306
Procainamide (Antiarrhythmic) Pathway	SMP00324
Propranolol Pathway	SMP00307
Quinapril Pathway	SMP00153
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Tocainide Pathway	SMP00330
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_1_Pfam_Domain_Function:
PF00520	Ion_trans

# Drug_Target_1_Protein_Sequence:
>Voltage-dependent L-type calcium channel subunit alpha-1C
MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAALSWQAAIDAAR
QAKLMGSAGNATISTVSSTQRKRQQYGKPKKQGSTTATRPPRALLCLTLKNPIRRACISI
VEWKPFEIIILLTIFANCVALAIYIPFPEDDSNATNSNLERVEYLFLIIFTVEAFLKVIA
YGLLFHPNAYLRNGWNLLDFIIVVVGLFSAILEQATKADGANALGGKGAGFDVKALRAFR
VLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFMGKMHKTCYN
QEGIADVPAEDDPSPCALETGHGRQCQNGTVCKPGWDGPKHGITNFDNFAFAMLTVFQCI
TMEGWTDVLYWVNDAVGRDWPWIYFVTLIIIGSFFVLNLVLGVLSGEFSKEREKAKARGD
FQKLREKQQLEEDLKGYLDWITQAEDIDPENEDEGMDEEKPRNMSMPTSETESVNTENVA
GGDIEGENCGARLAHRISKSKFSRYWRRWNRFCRRKCRAAVKSNVFYWLVIFLVFLNTLT
IASEHYNQPNWLTEVQDTANKALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCFVVCGGI
LETILVETKIMSPLGISVLRCVRLLRIFKITRYWNSLSNLVASLLNSVRSIASLLLLLFL
FIIIFSLLGMQLFGGKFNFDEMQTRRSTFDNFPQSLLTVFQILTGEDWNSVMYDGIMAYG
GPSFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLADAESLTSAQKEEEEEKERKKLAR
TASPEKKQELVEKPAVGESKEEKIELKSITADGESPPATKINMDDLQPNENEDKSPYPNP
ETTGEEDEEEPEMPVGPRPRPLSELHLKEKAVPMPEASAFFIFSSNNRFRLQCHRIVNDT
IFTNLILFFILLSSISLAAEDPVQHTSFRNHILFYFDIVFTTIFTIEIALKILGNADYVF
TSIFTLEIILKMTAYGAFLHKGSFCRNYFNILDLLVVSVSLISFGIQSSAINVVKILRVL
RVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIVIVTTLLQFMFACIGVQLFKGKLYTCSD
SSKQTEAECKGNYITYKDGEVDHPIIQPRSWENSKFDFDNVLAAMMALFTVSTFEGWPEL
LYRSIDSHTEDKGPIYNYRVEISIFFIIYIIIIAFFMMNIFVGFVIVTFQEQGEQEYKNC
ELDKNQRQCVEYALKARPLRRYIPKNQHQYKVWYVVNSTYFEYLMFVLILLNTICLAMQH
YGQSCLFKIAMNILNMLFTGLFTVEMILKLIAFKPKGYFSDPWNVFDFLIVIGSIIDVIL
SETNHYFCDAWNTFDALIVVGSIVDIAITEVNPAEHTQCSPSMNAEENSRISITFFRLFR
VMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQVFGKIALNDTTE
INRNNNFQTFPQAVLLLFRCATGEAWQDIMLACMPGKKCAPESEPSNSTEGETPCGSSFA
VFYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWAEYDPEAKGRI
KHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVSMNMPLNSDGTVMFNATLFALVRTALRI
KTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGDDEVTVGKFYATFLIQEYFRKFK
KRKEQGLVGKPSQRNALSLQAGLRTLHDIGPEIRRAISGDLTAEEELDKAMKEAVSAASE
DDIFRRAGGLFGNHVSYYQSDGRSAFPQTFTTQRPLHINKAGSSQGDTESPSHEKLVDST
FTPSSYSSTGSNANINNANNTALGRLPRPAGYPSTVSTVEGHGPPLSPAIRVQEVAWKLS
SNRERHVPVCEDLELRRDSGSAGTQAHCLLLRRANPSRCHSRESQAAMAGQEETSQDETY
EVKMNHDTEACSEPSLLSTEMLSYQDDENRQLTLPEEDKRDIRQSPKRGFLRSASLGRRA
SFHLECLKRQKDRGGDISQKTVLPLHLVHHQALAVAGLSPLLQRSHSPASFPRPFATPPA
TPGSRGWPPQPVPTLRLEGVESSEKLNSSFPSIHCGSWAETTPGGGGSSAARRVRPVSLM
VPSQAGAPGRQFHGSASSLVEAVLISEGLGQFAQDPKFIEVTTQELADACDMTIEEMESA
ADNILSGGAPQSPNGALLPFVNCRDAGQDRAGGEEDAGCVRARGAPSEEELQDSRVYVSS
L

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the "high-voltage activated" (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin- GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1C subunit play an important role in excitation-contraction coupling in the heart. The various isoforms display marked differences in the sensitivity to DHP compounds

# Drug_Target_1_SwissProt_ID:
Q13936

# Drug_Target_1_SwissProt_Name:
CAC1C_HUMAN

# Drug_Target_1_Synonyms:
Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle
Voltage- gated calcium channel subunit alpha Cav1.2

# Drug_Target_1_Theoretical_pI:
6.70

# Drug_Target_1_Transmembrane_Regions:
125-143
161-181
194-212
233-251
271-290
381-405
525-543
559-578
587-605
616-634
654-673
729-753
901-919
936-955
988-1006
1014-1032
1052-1071
1162-1186
1240-1258
1274-1293
1302-1320
1373-1391
1411-1430
1500-1524

# Drug_Target_2_Cellular_Location:
Cell membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CACNB2

# Drug_Target_2_GenBank_ID_Gene:
S60415

# Drug_Target_2_GenBank_ID_Protein:
300417

# Drug_Target_2_GeneCard_ID:
CACNB2

# Drug_Target_2_Gene_Name:
CACNB2

# Drug_Target_2_Gene_Sequence:
>1983 bp
ATGGTCCAAAGGGACATGTCCAAGTCGCCTCCCACAGCGGCGGCGGCGGTGGCGCAGGAG
ATCCAGATGGAACTGCTAGAGAACGTGGCTCCCGCGGGGGCGCTCGGAGCCGCCGCACAG
TCATATGGAAAAGGAGCCAGAAGGAAAAACAGATTTAAAGGATCTGATGGAAGCACGTCA
TCTGATACTACCTCAAATAGTTTTCTTCGCCAGGGTTCGGCAGACTCCTACACTAGCCGT
CCATCCGATTCCGATGTATCTCTGGAGGAGGACCGGGAGGCAGTGCGCAGAGAAGCGCAG
CAGGCCCAGGCACAGTTGGAAAAAGCAAAGACAAAGCCCGTTGCATTTGCGGTTCGGACA
GATGTCAGCTACAGTGCGGCCCATGAAGATGATGTTCCAGTGCCTGGCATGGCCATCTCA
TTCGAAGCAAAAGATTTTCTGCATGTTAAGGAAAAATTTAACAATGACTGGTGGATAGGG
CGATTGGTAAAAGAAGGCTGTGAAATCGGATTCATTCCAAGCCCAGTCAAACTAGAAAAC
ATGAGGCTGCAGCATGAACAGAGAGCCAAGCAAGGGAAATTCTACTCCAGTAAATCAGGA
GGAAATTCATCATCCAGTTTGGGTGACATAGTACCTAGTTCCAGAAAATCAACACCTCCA
TCATCTGCTATAGACATAGATGCTACTGGCTTAGATGCAGAAGAAAATGATATTCCAGCA
AACCACCGCTCCCCTAAACCCAGTGCAAACAGTGTAACGTCACCCCACTCCAAAGAGAAA
AGAATGCCCTTCTTTAAGAAGACAGAGCACACTCCTCCGTATGATGTGGTACCTTCCATG
CGACCAGTGGTCCTAGTGGGCCCTTCTCTGAAGGGCTACGAGGTCACAGATATGATGCAA
AAAGCGCTGTTTGATTTTTTAAAACACAGATTTGAAGGGCGGATATCCATCACAAGGGTC
ACCGCTGACATCTCGCTTGCCAAACGCTCGGTATTAAACAATCCCAGTAAGCACGCAATA
ATAGAAAGATCCAACACAAGGTCAAGCTTAGCGGAAGTTCAGAGTGAAATCGAAAGGATT
TTTGAAGTTGCAAGAACATTGCAGTTGGTGGTCCTTGACGCGGATACAATTAATCATCCA
GCTCAACTCAGTAAAACCTCCTTGGCCCCTATTATAGTATATGTAAAGATTTCTTCTCCT
AAGGTTTTACAAACCTTAATAAAATCTCGAGGGAAATCTCAAGCTAAACACCTCAACGTC
CAGATGGTAGCAGCTGATAAACTGGCTCAGTGTCCTCCAGAGCTGTTCGATGTGATCTTG
GATGAGAACCAGCTTGAGGATGCCTGTGAGCACCTTGCCGACTATCTGGAGGCCTACTGG
AAGGCCACCCATCCTCCCAGCAGTAGCCTCCCCAACCCTCTCCTTAGCCGTACATTAGCC
ACTTCAAGTCTGCCTCTTAGCCCCACCCTAGCCTCTAATTCACAGGGTTCTCAAGGTCAT
CAGAGGACTGATCGCTCCGCTCCTATCCGTTCTGCTTCCCAAGCTGAAGAAGAACCTAGT
GTGGAAGGAGTCAAGAAATCCCAGCACCGCTCTTCCTCCTCAGCCCCACACCACAACCAT
CGCAGTGGGACAAGTCGCGGCCTCTCCAGGCAAGAGACATTTGACTCGGAAACCCAGGAG
AGTCGAGACTCTGCCTACGTAGAGCCAAAGGAAGATTATTCCCATGACCACGTGGACCAC
TATGCCTCACACCGTGACCACAACCACAGAGACGAGACCCACGGGAGCAGTGACCACAGA
CACAGGGAGTCCCGGCACCGTTCCCGGGACGTGGATCGAGAGCAGGACCACAACGAGTGC
AACAAGCAGCAGCGCAGCCGTCATAAATCCAAGGATCGCTACTGTGAAAAGGATGGAGAA
GTGATATCAAAAAAACGGAATGAGGCTGGGGAGTGGAACAGGGATGTTTACATCCGCCAA
TGA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
8494331	Rosenfeld MR, Wong E, Dalmau J, Manley G, Posner JB, Sher E, Furneaux HM: Cloning and characterization of a Lambert-Eaton myasthenic syndrome antigen. Ann Neurol. 1993 Jan;33(1):113-20.
9254841	Taviaux S, Williams ME, Harpold MM, Nargeot J, Lory P: Assignment of human genes for beta 2 and beta 4 subunits of voltage-dependent Ca2+ channels to chromosomes 10p12 and 2q22-q23. Hum Genet. 1997 Aug;100(2):151-4.

# Drug_Target_2_HGNC_ID:
HGNC:1402

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4110

# Drug_Target_2_Locus:
10p12

# Drug_Target_2_Molecular_Weight:
73581

# Drug_Target_2_Name:
Voltage-dependent L-type calcium channel subunit beta-2

# Drug_Target_2_Number_of_Residues:
660

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Amlodipine Pathway	SMP00376
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Felodipine Pathway	SMP00377
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Isradipine Pathway	SMP00378
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lisinopril Pathway	SMP00150
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Procainamide (Antiarrhythmic) Pathway	SMP00324
Quinapril Pathway	SMP00153
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Tocainide Pathway	SMP00330
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_2_Pfam_Domain_Function:
PF00018	SH3_1
PF00774	Ca_channel_B

# Drug_Target_2_Protein_Sequence:
>Voltage-dependent L-type calcium channel subunit beta-2
MVQRDMSKSPPTAAAAVAQEIQMELLENVAPAGALGAAAQSYGKGARRKNRFKGSDGSTS
SDTTSNSFVRQGSADSYTSRPSDSDVSLEEDREAVRREAERQAQAQLEKAKTKPVAFAVR
TNVSYSAAHEDDVPVPGMAISFEAKDFLHVKEKFNNDWWIGRLVKEGCEIGFIPSPVKLE
NMRLQHEQRAKQGKFYSSKSGGNSSSSLGDIVPSSRKSTPPSSAIDIDATGLDAEENDIP
ANHRSPKPSANSVTSPHSKEKRMPFFKKTEHTPPYDVVPSMRPVVLVGPSLKGYEVTDMM
QKALFDFLKHRFEGRISITRVTADISLAKRSVLNNPSKHAIIERSNTRSSLAEVQSEIER
IFELARTLQLVVLDADTINHPAQLSKTSLAPIIVYVKISSPKVLQRLIKSRGKSQAKHLN
VQMVAADKLAQCPPELFDVILDENQLEDACEHLADYLEAYWKATHPPSSSLPNPLLSRTL
ATSSLPLSPTLASNSQGSQGDQRTDRSAPIRSASQAEEEPSVEPVKKSQHRSSSSAPHHN
HRSGTSRGLSRQETFDSETQESRDSAYVEPKEDYSHDHVDHYASHRDHNHRDETHGSSDH
RHRESRHRSRDVDREQDHNECNKQRSRHKSKDRYCEKDGEVISKKRNEAGEWNRDVYIRQ

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting

# Drug_Target_2_SwissProt_ID:
Q08289

# Drug_Target_2_SwissProt_Name:
CACB2_HUMAN

# Drug_Target_2_Synonyms:
CAB2
Calcium channel voltage-dependent subunit beta 2
Lambert-Eaton myasthenic syndrome antigen B
MYSB

# Drug_Target_2_Theoretical_pI:
8.26

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Membrane

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11160515	Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nurnberg B, Dolphin AC: Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents. J Neurophysiol. 2001 Feb;85(2):816-27.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
CACNA1D

# Drug_Target_3_GenBank_ID_Gene:
M76558

# Drug_Target_3_GenBank_ID_Protein:
179764

# Drug_Target_3_GeneCard_ID:
CACNA1D

# Drug_Target_3_Gene_Name:
CACNA1D

# Drug_Target_3_Gene_Sequence:
>6486 bp
ATGATGATGATGATGATGATGAAAAAAATGCAGCATCAACGGCAGCAGCAAGCGGACCAC
GCGAACGAGGCAAACTATGCAAGAGGCACCAGACTTCCTCTTTCTGGTGAAGGACCAACT
TCTCAGCCGAATAGCTCCAAGCAAACTGTCCTGTCTTGGCAAGCTGCAATCGATGCTGCT
AGACAGGCCAAGGCTGCCCAAACTATGAGCACCTCTGCACCCCCACCTGTAGGATCTCTC
TCCCAAAGAAAACGTCAGCAATACGCCAAGAGCAAAAAACAGGGTAACTCGTCCAACAGC
CGACCTGCCCGCGCCCTTTTCTGTTTATCACTCAATAACCCCATCCGAAGAGCCTGCATT
AGTATAGTGGAATGGAAACCATTTGACATATTTATATTATTGGCTATTTTTGCCAATTGT
GTGGCCTTAGCTATTTACATCCCATTCCCTGAAGATGATTCTAATTCAACAAATCATAAC
TTGGAAAAAGTAGAATATGCCTTCCTGATTATTTTTACAGTCGAGACATTTTTGAAGATT
ATAGCGTATGGATTATTGCTACATCCTAATGCTTATGTTAGGAATGGATGGAATTTACTG
GATTTTGTTATAGTAATAGTAGGATTGTTTAGTGTAATTTTGGAACAATTAACCAAAGAA
ACAGAAGGCGGGAACCACTCAAGCGGCAAATCTGGAGGCTTTGATGTCAAAGCCCTCCGT
GCCTTTCGAGTGTTGCGACCACTTCGACTAGTGTCAGGAGTGCCCAGTTTACAAGTTGTC
CTGAACTCCATTATAAAAGCCATGGTTCCCCTCCTTCACATAGCCCTTTTGGTATTATTT
GTAATCATAATCTATGCTATTATAGGATTGGAACTTTTTATTGGAAAAATGCACAAAACA
TGTTTTTTTGCTGACTCAGATATCGTAGCTGAAGAGGACCCAGCTCCATGTGCGTTCTCA
GGGAATGGACGCCAGTGTACTGCCAATGGCACGGAATGTAGGAGTGGCTGGGTTGGCCCG
AACGGAGGCATCACCAACTTTGATAACTTTGCCTTTGCCATGCTTACTGTGTTTCAGTGC
ATCACCATGGAGGGCTGGACAGACGTGCTCTACTGGATGAATGATGCTATGGGATTTGAA
TTGCCCTGGGTGTATTTTGTCAGTCTCGTCATCTTTGGGTCATTTTTCGTACTAAATCTT
GTACTTGGTGTATTGAGCGGAGAATTCTCAAAGGAAAGAGAGAAGGCAAAAGCACGGGGA
GATTTCCAGAAGCTCCGGGAGAAGCAGCAGCTGGAGGAGGATCTAAAGGGCTACTTGGAT
TGGATCACCCAAGCTGAGGACATCGATCCGGAGAATGAGGAAGAAGGAGGAGAGGAAGGC
AAACGAAATACTAGCATGCCCACCAGCGAGACTGAGTCTGTGAACACAGAGAACGTCAGC
GGTGAAGGCGAGAACCGAGGCTGCTGTGGAAGTCTCTGTCAAGCCATCTCAAAATCCAAA
CTCAGCCGACGCTGGCGTCGCTGGAACCGATTCAATCGCAGAAGATGTAGGGCCGCCGTG
AAGTCTGTCACGTTTTACTGGCTGGTTATCGTCCTGGTGTTTCTGAACACCTTAACCATT
TCCTCTGAGCACTACAATCAGCCAGATTGGTTGACACAGATTCAAGATATTGCCAACAAA
GTCCTCTTGGCTCTGTTCACCTGCGAGATGCTGGTAAAAATGTACAGCTTGGGCCTCCAA
GCATATTTCGTCTCTCTTTTCAACCGGTTTGATTGCTTCGTGGTGTGTGGTGGAATCACT
GAGACGATCTTGGTGGAACTGGAAATCATGTCTCCCCTGGGGATCTCTGTGTTTCGGTGT
GTGCGCCTCTTAAGAATCTTCAAAGTGACCAGGCACTGGACTTCCCTGTGCAACTTAGTG
GCATCCTTATTAAACTCCATGAAGTCCAGTGCTTCGCTGTTGCTTCTGCTTTTTCTCTTC
ATTATCATCTTTTCCTTGCTTGGGATGCAGCTGTTTGGCGGCAAGTTTAATTTTGATGAA
ACGCAAACCAAGCGGAGCACCTTTGACAATTTCCCTCAAGCACTTCTCACAGTGTTCCAG
ATCCTGACAGGCGAAGACTGGAATGCTGTGATGTACGATGGCATCATGGCTTACGGGGGC
CCATCCTCTTCAGGAATGATCGTCTGCATCTACTTCATCATCCTCTTCATTTGTGGTAAC
TATATTCTACTGAATGTCTTCTTGGCCATCGCTGTAGACAATTTGGCTGATGCTGAAAGT
CTGAACACTGCTCAGAAAGAAGAAGCGGAAGAAAAGGAGAGGAAAAAGATTGCCAGAAAA
GAGAGCCTAGAAAATAAAAAGAACAACAAACCAGAAGTCAACCAGATAGCCAACAGTGAC
AACAAGGTTACAATTGATGACTATAGAGAAGAGGATGAAGACAAGGACCCCTATCCGCCT
TGCGATGTGCCAGTAGGGGAAGAGGAAGAGGAAGAGGAGGAGGATGAACCTGAGGTTCCT
GCCGGACCCCGTCCTCGAAGGATCTCGGAGTTGAACATGAAGGAAAAAATTGCCCCCATC
CCTGAAGGGAGCGCTTTCTTCATTCTTAGCAAGACCAACCCGATCCGCGTAGGCTGCCAC
AAGCTCATCAACCACCACATCTTCACCAACCTCATCCTTGTCTTCATCATGCTGAGCAGT
GCTGCCCTGGCCGCAGAGGACCCCATCCGCAGCCACTCCTTCCGGAACACGATACTGGGT
TACTTTGACTATGCCTTCACAGCCATCTTTACTGTTGAGATCCTGTTGAAGATGACAACT
TTTGGAGCTTTCCTCCACAAAGGGGCCTTCTGCAGGAACTACTTCAATTTGCTGGATATG
CTGGTGGTTGGGGTGTCTCTGGTGTCATTTGGGATTCAATCCAGTGCCATCTCCGTTGTG
AAGATTCTGAGGGTCTTAAGGGTCCTGCGTCCCCTCAGGGCCATCAACAGAGCAAAAGGA
CTTAAGCACGTGGTCCAGTGCGTCTTCGTGGCCATCCGGACCATCGGCAACATCATGATC
GTCACCACCCTCCTGCAGTTCATGTTTGCCTGTATCGGGGTCCAGTTGTTCAAGGGGAAG
TTCTATCGCTGTACGGATGAAGCCAAAAGTAACCCTGAAGAATGCAGGGGACTTTTCATC
CTCTACAAGGATGGGGATGTTGACAGTCCTGTGGTCCGTGAACGGATCTGGCAAAACAGT
GATTTCAACTTCGACAACGTCCTCTCTGCTATGATGGCGCTCTTCACAGTCTCCACGTTT
GAGGGCTGGCCTGCGTTGCTGTATAAAGCCATCGACTCGAATGGAGAGAACATCGGCCCA
ATCTACAACCACCGCGTGGAGATCTCCATCTTCTTCATCATCTACATCATCATTGTAGCT
TTCTTCATGATGAACATCTTTGTGGGCTTTGTCATCGTTACATTTCAGGAACAAGGAGAA
AAAGAGTATAAGAACTGTGAGCTGGACAAAAATCAGCGTCAGTGTGTTGAATACGCCTTG
AAAGCACGTCCCTTGCGGAGATACATCCCCAAAAACCCCTACCAGTACAAGTTCTGGTAC
GTGGTGAACTCTTCGCCTTTCGAATACATGATGTTTGTCCTCATCATGCTCAACACACTC
TGCTTGGCCATGCAGCACTACGAGCAGTCCAAGATGTTCAATGATGCCATGGACATTCTG
AACATGGTCTTCACCGGGGTGTTCACCGTCGAGATGGTTTTGAAAGTCATCGCATTTAAG
CCTAAGGGGTATTTTAGTGACGCCTGGAACACGTTTGACTCCCTCATCGTAATCGGCAGC
ATTATAGACGTGGCCCTCAGCGAAGCAGACCCAACTGAAAGTGAAAATGTCCCTGTCCCA
ACTGCTACACCTGGGAACTCTGAAGAGAGCAATAGAATCTCCATCACCTTTTTCCGTCTT
TTCCGAGTGATGCGATTGGTGAAGCTTCTCAGCAGGGGGGAAGGCATCCGGACATTGCTG
TGGACTTTTATTAAGTTCTTTCAGGCGCTCCCGTATGTGGCCCTCCTCATAGCCATGCTG
TTCTTCATCTATGCGGTCATTGGCATGCAGATGTTTGGGAAAGTTGCCATGAGAGATAAC
AACCAGATCAATAGGAACAATAACTTCCAGACGTTTCCCCAGGCGGTGCTGCTGCTCTTC
AGGTGTGCAACAGGTGAGGCCTGGCAGGAGATCATGCTGGCCTGTCTCCCAGGGAAGCTC
TGTGACCCTGAGTCAGATTACAACCCCGGGGAGGAGCATACATGTGGGAGCAACTTTGCC
ATTGTCTATTTCATCAGTTTTTACATGCTCTGTGCATTTCTGATCATCAATCTGTTTGTG
GCTGTCATCATGGATAATTTCGACTATCTGACCCGGGACTGGTCTATTTTGGGGCCTCAC
CATTTAGATGAATTCAAAAGAATATGGTCAGAATATGACCCTGAGGCAAAGGGAAGGATA
AAACACCTTGATGTGGTCACTCTGCTTCGACGCATCCAGCCTCCCCTGGGGTTTGGGAAG
TTATGTCCACACAGGGTAGCGTGCAAGAGATTAGTTGCCATGAACATGCCTCTCAACAGT
GACGGGACAGTCATGTTTAATGCAACCCTGTTTGCTTTGGTTCGAACGGCTCTTAAGATC
AAGACCGAAGGGAACCTGGAGCAAGCTAATGAAGAACTTCGGGCTGTGATAAAGAAAATT
TGGAAGAAAACCAGCATGAAATTACTTGACCAAGTTGTCCCTCCAGCTGGTGATGATGAG
GTAACCGTGGGGAAGTTCTATGCCACTTTCCTGATACAGGACTACTTTAGGAAATTCAAG
AAACGGAAAGAACAAGGACTGGTGGGAAAGTACCCTGCGAAGAACACCACAATTGCCCTA
CAGGCGGGATTAAGGACACTGCATGACATTGGGCCAGAAATCCGGCGTGCTATATCGTGT
GATTTGCAAGATGACGAGCCTGAGGAAACAAAACGAGAAGAAGAAGATGATGTGTTCAAA
AGAAATGGTGCCCTGCTTGGAAACCATGTCAATCATGTTAATAGTGATAGGAGAGATTCC
CTTCAGCAGACCAATACCACCCACCGTCCCCTGCATGTCCAAAGGCCTTCAATTCCACCT
GCAAGTGATACTGAGAAACCGCTGTTTCCTCCAGCAGGAAATTCGGTGTGTCATAACCAT
CATAACCATAATTCCATAGGAAAGCAAGTTCCCACCTCAACAAATGCCAATCTCAATAAT
GCCAATATGTCCAAAGCTGCCCATGGAAAGCGGCCCAGCATTGGGAACCTTGAGCATGTG
TCTGAAAATGGGCATCATTCTTCCCACAAGCATGACCGGGAGCCTCAGAGAAGGTCCAGT
GTGAAAAGAACCCGCTATTATGAAACTTACATTAGGTCCGACTCAGGAGATGAACAGCTC
CCAACTATTTGCCGGGAAGACCCAGAGATACATGGCTATTTCAGGGACCCCCACTGCTTG
GGGGAGCAGGAGTATTTCAGTAGTGAGGAATGCTACGAGGATGACAGCTCGCCCACCTGG
AGCAGGCAAAACTATGGCTACTACAGCAGATACCCAGGCAGAAACATCGACTCTGAGAGG
CCCCGAGGCTACCATCATCCCCAAGGATTCTTGGAGGACGATGACTCGCCCGTTTGCTAT
GATTCACGGAGATCTCCAAGGAGACGCCTACTACCTCCCACCCCAGCATCCCACCGGAGA
TCCTCCTTCAACTTTGAGTGCCTGCGCCGGCAGAGCAGCCAGGAAGAGGTCCCGTCGTCT
CCCATCTTCCCCCATCGCACGGCCCTGCCTCTGCATCTAATGCAGCAACAGATCATGGCA
GTTGCCGGCCTAGATTCAAGTAAAGCCCAGAAGTACTCACCGAGTCACTCGACCCGGTCG
TGGGCCACCCCTCCAGCAACCCCTCCCTACCGGGACTGGACACCGTGCTACACCCCCCTG
ATCCAAGTGGAGCAGTCAGAGGCCCTGGACCAGGTGAACGGCAGCCTGCCGTCCCTGCAC
CGCAGCTCCTGGTACACAGACGAGCCCGACATCTCCTACCGGACTTTCACACCAGCCAGC
CTGACTGTCCCCAGCAGCTTCCGGAACAAAAACAGCGACAAGCAGAGGAGTGCGGACAGC
TTGGTGGAGGCAGTCCTGATATCCGAAGGCTTGGGACGCTATGCAAGGGACCCAAAATTT
GTGTCAGCAACAAAACACGAAATCGCTGATGCCTGTGACCTCACCATCGACGAGATGGAG
AGTGCAGCCAGCACCCTGCTTAATGGGAACGTGCGTCCCCGAGCCAACGGGGATGTGGGC
CCCCTCTCACACCGGCAGGACTATGAGCTACAGGACTTTGGTCCTGGCTACAGCGACGAA
GAGCCAGACCCTGGGAGGGATGAGGAGGACCTGGCGGATGAAATGATATGCATCACCACC
TTGTAG

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
1309651	Williams ME, Feldman DH, McCue AF, Brenner R, Velicelebi G, Ellis SB, Harpold MM: Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype. Neuron. 1992 Jan;8(1):71-84.
1309948	Seino S, Chen L, Seino M, Blondel O, Takeda J, Johnson JH, Bell GI: Cloning of the alpha 1 subunit of a voltage-dependent calcium channel expressed in pancreatic beta cells. Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):584-8.
7557998	Yamada Y, Masuda K, Li Q, Ihara Y, Kubota A, Miura T, Nakamura K, Fujii Y, Seino S, Seino Y: The structures of the human calcium channel alpha 1 subunit (CACNL1A2) and beta subunit (CACNLB3) genes. Genomics. 1995 May 20;27(2):312-9.

# Drug_Target_3_HGNC_ID:
HGNC:1391

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4115

# Drug_Target_3_Locus:
3p14.3

# Drug_Target_3_Molecular_Weight:
245144

# Drug_Target_3_Name:
Voltage-dependent L-type calcium channel subunit alpha-1D

# Drug_Target_3_Number_of_Residues:
2161

# Drug_Target_3_PDB_ID:
1VYT

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00520	Ion_trans
PF08763	Ca_chan_IQ

# Drug_Target_3_Protein_Sequence:
>Voltage-dependent L-type calcium channel subunit alpha-1D
MMMMMMMKKMQHQRQQQADHANEANYARGTRLPLSGEGPTSQPNSSKQTVLSWQAAIDAA
RQAKAAQTMSTSAPPPVGSLSQRKRQQYAKSKKQGNSSNSRPARALFCLSLNNPIRRACI
SIVEWKPFDIFILLAIFANCVALAIYIPFPEDDSNSTNHNLEKVEYAFLIIFTVETFLKI
IAYGLLLHPNAYVRNGWNLLDFVIVIVGLFSVILEQLTKETEGGNHSSGKSGGFDVKALR
AFRVLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFIGKMHKT
CFFADSDIVAEEDPAPCAFSGNGRQCTANGTECRSGWVGPNGGITNFDNFAFAMLTVFQC
ITMEGWTDVLYWMNDAMGFELPWVYFVSLVIFGSFFVLNLVLGVLSGEFSKEREKAKARG
DFQKLREKQQLEEDLKGYLDWITQAEDIDPENEEEGGEEGKRNTSMPTSETESVNTENVS
GEGENRGCCGSLCQAISKSKLSRRWRRWNRFNRRRCRAAVKSVTFYWLVIVLVFLNTLTI
SSEHYNQPDWLTQIQDIANKVLLALFTCEMLVKMYSLGLQAYFVSLFNRFDCFVVCGGIT
ETILVELEIMSPLGISVFRCVRLLRIFKVTRHWTSLSNLVASLLNSMKSIASLLLLLFLF
IIIFSLLGMQLFGGKFNFDETQTKRSTFDNFPQALLTVFQILTGEDWNAVMYDGIMAYGG
PSSSGMIVCIYFIILFICGNYILLNVFLAIAVDNLADAESLNTAQKEEAEEKERKKIARK
ESLENKKNNKPEVNQIANSDNKVTIDDYREEDEDKDPYPPCDVPVGEEEEEEEEDEPEVP
AGPRPRRISELNMKEKIAPIPEGSAFFILSKTNPIRVGCHKLINHHIFTNLILVFIMLSS
AALAAEDPIRSHSFRNTILGYFDYAFTAIFTVEILLKMTTFGAFLHKGAFCRNYFNLLDM
LVVGVSLVSFGIQSSAISVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIMI
VTTLLQFMFACIGVQLFKGKFYRCTDEAKSNPEECRGLFILYKDGDVDSPVVRERIWQNS
DFNFDNVLSAMMALFTVSTFEGWPALLYKAIDSNGENIGPIYNHRVEISIFFIIYIIIVA
FFMMNIFVGFVIVTFQEQGEKEYKNCELDKNQRQCVEYALKARPLRRYIPKNPYQYKFWY
VVNSSPFEYMMFVLIMLNTLCLAMQHYEQSKMFNDAMDILNMVFTGVFTVEMVLKVIAFK
PKGYFSDAWNTFDSLIVIGSIIDVALSEADPTESENVPVPTATPGNSEESNRISITFFRL
FRVMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIAMLFFIYAVIGMQMFGKVAMRDN
NQINRNNNFQTFPQAVLLLFRCATGEAWQEIMLACLPGKLCDPESDYNPGEEYTCGSNFA
IVYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWSEYDPEAKGRI
KHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVAMNMPLNSDGTVMFNATLFALVRTALKI
KTEGNLEQANEELRAVIKKIWKKTSMKLLDQVVPPAGDDEVTVGKFYATFLIQDYFRKFK
KRKEQGLVGKYPAKNTTIALQAGLRTLHDIGPEIRRAISCDLQDDEPEETKREEEDDVFK
RNGALLGNHVNHVNSDRRDSLQQTNTTHRPLHVQRPSIPPASDTEKPLFPPAGNSVCHNH
HNHNSIGKQVPTSTNANLNNANMSKAAHGKRPSIGNLEHVSENGHHSSHKHDREPQRRSS
VKRTRYYETYIRSDSGDEQLPTICREDPEIHGYFRDPHCLGEQEYFSSEECYEDDSSPTW
SRQNYGYYSRYPGRNIDSERPRGYHHPQGFLEDDDSPVCYDSRRSPRRRLLPPTPASHRR
SSFNFECLRRQSSQEEVPSSPIFPHRTALPLHLMQQQIMAVAGLDSSKAQKYSPSHSTRS
WATPPATPPYRDWTPCYTPLIQVEQSEALDQVNGSLPSLHRSSWYTDEPDISYRTFTPAS
LTVPSSFRNKNSDKQRSADSLVEAVLISEGLGRYARDPKFVSATKHEIADACDLTIDEME
SAASTLLNGNVRPRANGDVGPLSHRQDYELQDFGPGYSDEEPDPGRDEEDLADEMICITT
L

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the "high-voltage activated" (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin- GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA)

# Drug_Target_3_SwissProt_ID:
Q01668

# Drug_Target_3_SwissProt_Name:
CAC1D_HUMAN

# Drug_Target_3_Synonyms:
Calcium channel, L type, alpha-1 polypeptide, isoform 2
Voltage- gated calcium channel subunit alpha Cav1.3

# Drug_Target_3_Theoretical_pI:
6.73

# Drug_Target_3_Transmembrane_Regions:
127-145
164-183
196-214
236-254
274-293
382-406
524-543
559-577
586-604
615-633
653-673
728-752
887-905
922-941
954-972
979-998
1018-1037
1128-1148
1206-1224
1240-1259
1267-1288
1314-1333
1353-1372
1440-1464

# Drug_Target_4_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
CACNA2D1

# Drug_Target_4_GenBank_ID_Gene:
M76559

# Drug_Target_4_GenBank_ID_Protein:
179762

# Drug_Target_4_GeneCard_ID:
CACNA2D1

# Drug_Target_4_Gene_Name:
CACNA2D1

# Drug_Target_4_Gene_Sequence:
>3276 bp
ATGGCTGCTGGCTGCCTGCTGGCCTTGACTCTGACACTTTTCCAATCTTTGCTCATCGGC
CCCTCGTCGGAGGAGCCGTTCCCTTCGGCCGTCACTATCAAATCATGGGTGGATAAGATG
CAAGAAGACCTTGTCACACTGGCAAAAACAGCAAGTGGAGTCAATCAGCTTGTTGATATT
TATGAGAAATATCAAGATTTGTATACTGTGGAACCAAATAATGCACGCCAGCTGGTAGAA
ATTGCAGCCAGGGATATTGAGAAACTTCTGAGCAACAGATCTAAAGCCCTGGTGAGCCTG
GCATTGGAAGCGGAGAAAGTTCAAGCAGCTCACCAGTGGAGAGAAGATTTTGCAAGCAAT
GAAGTTGTCTACTACAATGCAAAGGATGATCTCGATCCTGAGAAAAATGACAGTGAGCCA
GGCAGCCAGAGGATAAAACCTGTTTTCATTGAAGATGCTAATTTTGGACGACAAATATCT
TATCAGCACGCAGCAGTCCATATTCCTACTGACATCTATGAGGGCTCAACAATTGTGTTA
AATGAACTCAACTGGACAAGTGCCTTAGATGAAGTTTTCAAAAAGAATCGCGAGGAAGAC
CCTTCATTATTGTGGCAGGTTTTTGGCAGTGCCACTGGCCTAGCTCGATATTATCCAGCT
TCACCATGGGTTGATAATAGTAGAACTCCAAATAAGATTGACCTTTATGATGTACGCAGA
AGACCATGGTACATCCAAGGAGCTGCATCTCCTAAAGACATGCTTATTCTGGTGGATGTG
AGTGGAAGTGTTAGTGGATTGACACTTAAACTGATCCGAACATCTGTCTCCGAAATGTTA
GAAACCCTCTCAGATGATGATTTCGTGAATGTAGCTTCATTTAACAGCAATGCTCAGGAT
GTAAGCTGTTTTCAGCACCTTGTCCAAGCAAATGTAAGAAATAAAAAAGTGTTGAAAGAC
GCGGTGAATAATATCACAGCCAAAGGAATTACAGATTATAAGAAGGGCTTTAGTTTTGCT
TTTGAACAGCTGCTTAATTATAATGTTTCCAGAGCAAACTGCAATAAGATTATTATGCTA
TTCACGGATGGAGGAGAAGAGAGAGCCCAGGAGATATTTAACAAATACAATAAAGATAAA
AAAGTACGTGTATTCAGGTTTTCAGTTGGTCAACACAATTATGAGAGAGGACCTATTCAG
TGGATGGCCTGTGAAAACAAAGGTTATTATTATGAAATTCCTTCCATTGGTGCAATAAGA
ATCAATACTCAGGAATATTTGGATGTTTTGGGAAGACCAATGGTTTTAGCAGGAGACAAA
GCTAAGCAAGTCCAATGGACAAATGTGTACCTGGATGCATTGGAACTGGGACTTGTCATT
ACTGGAACTCTTCCGGTCTTCAACATAACCGGCCAATTTGAAAATAAGACAAACTTAAAG
AACCAGCTGATTCTTGGTGTGATGGGAGTAGATGTGTCTTTGGAAGATATTAAAAGACTG
ACACCACGTTTTACACTGTGCCCCAATGGGTATTACTTTGCAATCGATCCTAATGGTTAT
GTTTTATTACATCCAAATCTTCAGCCAAAGAACCCCAAATCTCAGGAGCCAGTAACATTG
GATTTCCTTGATGCAGAGTTAGAGAATGATATTAAAGTGGAGATTCGAAATAAGATGATT
GATGGGGAAAGTGGAGAAAAAACATTCAGAACTCTGGTTAAATCTCAAGATGAGAGATAT
ATTGACAAAGGAAACAGGACATACACATGGACACCTGTCAATGGCACAGATTACAGTTTG
GCCTTGGTATTACCAACCTACAGTTTTTACTATATAAAAGCCAAACTAGAAGAGACAATA
ACTCAGGCCAGATCAAAAAAGGGCAAAATGAAGGATTCGGAAACCCTGAAGCCAGATAAT
TTTGAAGAATCTGGCTATACATTCATAGCACCAAGAGATTACTGCAATGACCTGAAAATA
TCGGATAATAACACTGAATTTCTTTTAAATTTCAACGAGTTTATTGATAGAAAAACTCCA
AACAACCCATCATGTAACGCGGATTTGATTAATAGAGTCTTGCTTGATGCAGGCTTTACA
AATGAACTTGTCCAAAATTACTGGAGTAAGCAGAAAAATATCAAGGGAGTGAAAGCACGA
TTTGTTGTGACTGATGGTGGGATTACCAGAGTTTATCCCAAAGAGGCTGGAGAAAATTGG
CAAGAAAACCCAGAGACATATGAGGACAGCTTCTATAAAAGGAGCCTAGATAATGATAAC
TATGTTTTCACTGCTCCCTACTTTAACAAAAGTGGACCTGGTGCCTATGAATCGGGCATT
ATGGTAAGCAAAGCTGTAGAAATATATATTCAAGGGAAACTTCTTAAACCTGCAGTTGTT
GGAATTAAAATTGATGTAAATTCCTGGATAGAGAATTTCACCAAAACCTCAATCAGAGAT
CCGTGTGCTGGTCCAGTTTGTGACTGCAAAAGAAACAGTGACGTAATGGATTGTGTGATT
CTGGATGATGGTGGGTTTCTTCTGATGGCAAATCATGATGATTATACTAATCAGATTGGA
AGATTTTTTGGAGAGATTGATCCCAGCTTGATGAGACACCTGGTTAATATATCAGTTTAT
GCTTTTAACAAATCTTATGATTATCAGTCAGTATGTGAGCCCGGTGCTGCACCAAAACAA
GGAGCAGGACATCGCTCAGCATATGTGCCATCAGTAGCAGACATATTACAAATTGGCTGG
TGGGCCACTGCTGCTGCCTGGTCTATTCTACAGCAGTTTCTCTTGAGTTTGACCTTTCCA
CGACTCCTTGAGGCAGTTGAGATGGAGGATGATGACTTCACGGCCTCCCTGTCCAAGCAG
AGCTGCATTACTGAACAAACCCAGTATTTCTTCGATAACGACAGTAAATCATTCAGTGGT
GTATTAGACTGTGGAAACTGTTCCAGAATCTTTCATGGAGAAAAGCTTATGAACACCAAC
TTAATATTCATAATGGTTGAGAGCAAAGGGACATGTCCATGTGACACACGACTGCTCATA
CAAGCGGAGCAGACTTCTGACGGTCCAAATCCTTGTGACATGGTTAAGCAACCTAGATAC
CGAAAAGGGCCTGATGTCTGCTTTGATAACAATGTCTTGGAGGATTATACTGACTGTGGT
GGTGTTTCTGGATTAAATCCCTCCCTGTGGTATATCATTGGAATCCAGTTTCTACTACTT
TGGCTGGTATCTGGCAGCACACACCGGCTGTTATGA

# Drug_Target_4_General_Function:
Cell motility

# Drug_Target_4_General_References:
1309651	Williams ME, Feldman DH, McCue AF, Brenner R, Velicelebi G, Ellis SB, Harpold MM: Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype. Neuron. 1992 Jan;8(1):71-84.
16335952	Liu T, Qian WJ, Gritsenko MA, Camp DG 2nd, Monroe ME, Moore RJ, Smith RD: Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res. 2005 Nov-Dec;4(6):2070-80.

# Drug_Target_4_HGNC_ID:
HGNC:1399

# Drug_Target_4_HPRD_ID:
00245

# Drug_Target_4_ID:
762

# Drug_Target_4_Locus:
7q21-q22

# Drug_Target_4_Molecular_Weight:
123184

# Drug_Target_4_Name:
Voltage-dependent calcium channel subunit alpha-2/delta-1

# Drug_Target_4_Number_of_Residues:
1091

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00092	VWA
PF02743	Cache_1
PF08399	VWA_N
PF08473	VGCC_alpha2

# Drug_Target_4_Protein_Sequence:
>Voltage-dependent calcium channel subunit alpha-2/delta-1
MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDI
YEKYQDLYTVEPNNARQLVEIAARDIEKLLSNRSKALVSLALEAEKVQAAHQWREDFASN
EVVYYNAKDDLDPEKNDSEPGSQRIKPVFIEDANFGRQISYQHAAVHIPTDIYEGSTIVL
NELNWTSALDEVFKKNREEDPSLLWQVFGSATGLARYYPASPWVDNSRTPNKIDLYDVRR
RPWYIQGAASPKDMLILVDVSGSVSGLTLKLIRTSVSEMLETLSDDDFVNVASFNSNAQD
VSCFQHLVQANVRNKKVLKDAVNNITAKGITDYKKGFSFAFEQLLNYNVSRANCNKIIML
FTDGGEERAQEIFNKYNKDKKVRVFRFSVGQHNYERGPIQWMACENKGYYYEIPSIGAIR
INTQEYLDVLGRPMVLAGDKAKQVQWTNVYLDALELGLVITGTLPVFNITGQFENKTNLK
NQLILGVMGVDVSLEDIKRLTPRFTLCPNGYYFAIDPNGYVLLHPNLQPKNPKSQEPVTL
DFLDAELENDIKVEIRNKMIDGESGEKTFRTLVKSQDERYIDKGNRTYTWTPVNGTDYSL
ALVLPTYSFYYIKAKLEETITQARSKKGKMKDSETLKPDNFEESGYTFIAPRDYCNDLKI
SDNNTEFLLNFNEFIDRKTPNNPSCNADLINRVLLDAGFTNELVQNYWSKQKNIKGVKAR
FVVTDGGITRVYPKEAGENWQENPETYEDSFYKRSLDNDNYVFTAPYFNKSGPGAYESGI
MVSKAVEIYIQGKLLKPAVVGIKIDVNSWIENFTKTSIRDPCAGPVCDCKRNSDVMDCVI
LDDGGFLLMANHDDYTNQIGRFFGEIDPSLMRHLVNISVYAFNKSYDYQSVCEPGAAPKQ
GAGHRSAYVPSVADILQIGWWATAAAWSILQQFLLSLTFPRLLEAVEMEDDDFTASLSKQ
SCITEQTQYFFDNDSKSFSGVLDCGNCSRIFHGEKLMNTNLIFIMVESKGTCPCDTRLLI
QAEQTSDGPNPCDMVKQPRYRKGPDVCFDNNVLEDYTDCGGVSGLNPSLWYIIGIQFLLL
WLVSGSTHRLL

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-24

# Drug_Target_4_Specific_Function:
Calcium channel protein which plays an important role in excitation-contraction coupling

# Drug_Target_4_SwissProt_ID:
P54289

# Drug_Target_4_SwissProt_Name:
CA2D1_HUMAN

# Drug_Target_4_Synonyms:
Dihydropyridine-sensitive L-type calcium channel subunits alpha- 2/delta precursor

# Drug_Target_4_Theoretical_pI:
4.86

# Drug_Target_4_Transmembrane_Regions:
446-469906-9301067-1086

# Drug_Target_5_Cellular_Location:
Cytoplasmic

# Drug_Target_5_Chromosome_Location:
2

# Drug_Target_5_Drug_References:
9231746	Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
U40370

# Drug_Target_5_GenBank_ID_Protein:
1151109

# Drug_Target_5_GeneCard_ID:
PDE1A

# Drug_Target_5_Gene_Name:
PDE1A

# Drug_Target_5_Gene_Sequence:
>1608 bp
ATGGGGTCTAGTGCCACAGAGATTGAAGAATTGGAAAACACCACTTTTAAGTATCTTACA
GGAGAACAGACTGAAAAAATGTGGCAGCGCCTGAAAGGAATACTAAGATGCTTGGTGAAG
CAGCTGGAAAGAGGTGATGTTAACGTCGTCGACTTAAAGAAGAATATTGAATATGCGGCA
TCTGTGCTGGAAGCAGTTTATATCGATGAAACAAGAAGACTTCTGGATACTGAAGATGAG
CTCAGTGACATTCAGACTGACTCAGTCCCATCTGAAGTCCGGGACTGGTTGGCTTCTACC
TTTACACGGAAAATGGGGATGACAAAAAAGAAACCTGAGGAAAAACCAAAATTTCGGAGC
ATTGTGCATGCTGTTCAAGCTGGAATTTTTGTGGAAAGAATGTACCGAAAAACATATCAT
ATGGTTGGTTTGGCATATCCAGCAGCTGTCATCGTAACATTAAAGGATGTTGATAAATGG
TCTTTCGATGTATTTGCCCTAAATGAAGCAAGTGGAGAGCATAGTCTGAAGTTTATGATT
TATGAACTGTTTACCAGATATGATCTTATCAACCGTTTCAAGATTCCTGTTTCTTGCCTA
ATCACCTTTGCAGAAGCTTTAGAAGTTGGTTACAGCAAGTACAAAAATCCATATCACAAT
TTGATTCATGCAGCTGATGTCACTCAAACTGTGCATTACATAATGCTTCATACAGGTATC
ATGCACTGGCTCACTGAACTGGAAATTTTAGCAATGGTCTTTGCTGCTGCCATTCATGAT
TATGAGCATACAGGGACAACAAACAACTTTCACATTCAGACAAGGTCAGATGTTGCCATT
TTGTATAATGATCGCTCTGTCCTTGAGAATCACCACGTGAGTGCAGCTTATCGACTTATG
CAAGAAGAAGAAATGAATATCTTGATAAATTTATCCAAAGATGACTGGAGGGATCTTCGG
AACCTAGTGATTGAAATGGTTTTATCTACAGACATGTCAGGTCACTTCCAGCAAATTAAA
AATATAAGAAACAGTTTGCAGCAGCCTGAAGGGATTGACAGAGCCAAAACCATGTCCCTG
ATTCTCCACGCAGCAGACATCAGCCACCCAGCCAAATCCTGGAAGCTGCATTATCGGTGG
ACCATGGCCCTAATGGAGGAGTTTTTCCTGCAGGGAGATAAAGAAGCTGAATTAGGGCTT
CCATTTTCCCCACTTTGTGATCGGAAGTCAACCATGGTGGCCCAGTCACAAATAGGTTTC
ATCGATTTCATAGTAGAGCCAACATTTTCTCTTCTGACAGACTCAACAGAGAAAATTGTT
ATTCCTCTTATAGAGGAAGCCTCAAAAGCCGAAACTTCTTCCTATGTGGCAAGCAGCTCA
ACCACCATTGTGGGGTTACACATTGCTGATGCACTAAGACGATCAAATACAAAAGGCTCC
ATGAGTGATGGGTCCTATTCCCCAGACTACTCCCTTGCAGCAGTGGACCTGAAGAGTTTC
AAGAACAACCTGGTGGACATCATTCAGCAGAACAAAGAGAGGTGGAAAGAGTTAGCTGCA
CAAGAAGCAAGAACCAGTTCACAGAAGTGTGAGTTTATTCATCAGTAA

# Drug_Target_5_General_Function:
Involved in calmodulin binding

# Drug_Target_5_General_References:
11342109	Michibata H, Yanaka N, Kanoh Y, Okumura K, Omori K: Human Ca2+/calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic organization, and chromosomal localization. Biochim Biophys Acta. 2001 Jan 26;1517(2):278-87.
11747989	Fidock M, Miller M, Lanfear J: Isolation and differential tissue distribution of two human cDNAs encoding PDE1 splice variants. Cell Signal. 2002 Jan;14(1):53-60.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
17974005	Bechtel S, Rosenfelder H, Duda A, Schmidt CP, Ernst U, Wellenreuther R, Mehrle A, Schuster C, Bahr A, Blocker H, Heubner D, Hoerlein A, Michel G, Wedler H, Kohrer K, Ottenwalder B, Poustka A, Wiemann S, Schupp I: The full-ORF clone resource of the German cDNA Consortium. BMC Genomics. 2007 Oct 31;8:399.
8557689	Loughney K, Martins TJ, Harris EA, Sadhu K, Hicks JB, Sonnenburg WK, Beavo JA, Ferguson K: Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases. J Biol Chem. 1996 Jan 12;271(2):796-806.

# Drug_Target_5_HGNC_ID:
GNC:8774

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
6047

# Drug_Target_5_Locus:
2q32.1

# Drug_Target_5_Molecular_Weight:
61251.4

# Drug_Target_5_Name:
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A

# Drug_Target_5_Number_of_Residues:
535

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00233	PDEase_I
PF08499	PDEase_I_N

# Drug_Target_5_Protein_Sequence:
>Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
MGSSATEIEELENTTFKYLTGEQTEKMWQRLKGILRCLVKQLERGDVNVVDLKKNIEYAA
SVLEAVYIDETRRLLDTEDELSDIQTDSVPSEVRDWLASTFTRKMGMTKKKPEEKPKFRS
IVHAVQAGIFVERMYRKTYHMVGLAYPAAVIVTLKDVDKWSFDVFALNEASGEHSLKFMI
YELFTRYDLINRFKIPVSCLITFAEALEVGYSKYKNPYHNLIHAADVTQTVHYIMLHTGI
MHWLTELEILAMVFAAAIHDYEHTGTTNNFHIQTRSDVAILYNDRSVLENHHVSAAYRLM
QEEEMNILINLSKDDWRDLRNLVIEMVLSTDMSGHFQQIKNIRNSLQQPEGIDRAKTMSL
ILHAADISHPAKSWKLHYRWTMALMEEFFLQGDKEAELGLPFSPLCDRKSTMVAQSQIGF
IDFIVEPTFSLLTDSTEKIVIPLIEEASKAETSSYVASSSTTIVGLHIADALRRSNTKGS
MSDGSYSPDYSLAAVDLKSFKNNLVDIIQQNKERWKELAAQEARTSSQKCEFIHQ

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Has a higher affinity for cGMP than for cAMP

# Drug_Target_5_SwissProt_ID:
P54750

# Drug_Target_5_SwissProt_Name:
PDE1A_HUMAN

# Drug_Target_5_Synonyms:
61 kDa Cam-PDE
Cam-PDE 1A
hCam-1

# Drug_Target_5_Theoretical_pI:
6.02

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
9231746	Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
PDE1B

# Drug_Target_6_GenBank_ID_Gene:
U56976

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
PDE1B

# Drug_Target_6_Gene_Sequence:
>1611 bp
ATGGAGCTGTCCCCCCGCAGTCCTCCGGAGATGCTGGAGGAGTCGGATTGCCCGTCACCC
CTGGAGCTGAAGTCAGCCCCCAGCAAGAAGATGTGGATTAAGCTTCGGTCTCTGCTGCGC
TACATGGTGAAGCAGTTGGAGAATGGGGAGATAAACATTGAGGAGCTGAAGAAAAATCTG
GAGTACACAGCTTCTCTGCTGGAAGCCGTCTACATAGATGAGACACGGCAAATCTTGGAC
ACGGAGGACGAGCTGCAGGAGCTGCGGTCAGATGCCGTGCCTTCGGAGGTGCGGGACTGG
CTGGCCTCCACCTTCACCCAGCAGGCCCGGGCCAAAGGCCGCCGAGCAGAGGAGAAGCCC
AAGTTCCGAAGCATTGTGCACGCTGTGCAGGCTGGGATCTTCGTGGAACGGATGTTCCGG
AGAACATACACCTCTGTGGGCCCCACTTACTCTACTGCGGTTCTCAACTGTCTCAAGAAC
CTGGATCTCTGGTGCTTTGATGTCTTTTCCTTGAACCAGGCAGCAGATGACCATGCCCTG
AGGACCATTGTTTTTGAGTTGCTGACTCGGCATAACCTCATCAGCCGCTTCAAGATTCCC
ACTGTGTTTTTGATGAGTTTCCTGGATGCCTTGGAGACAGGCTATGGGAAGTACAAGAAT
CCTTACCACAACCAGATCCACGCAGCCGATGTTACCCAGACAGTCCATTGCTTCTTGCTC
CGCACAGGGATGGTGCACTGCCTGTCGGAGATTGAGCTCCTGGCCATCATCTTTGCTGCA
GCTATCCATGATTATGAGCACACGGGCACTACCAACAGCTTCCACATCCAGACCAAGTCA
GAATGTGCCATCGTGTACAATGATCGTTCAGTGCTGGAGAATCACCACATCAGCTCTGTT
TTCCGATTGATGCAGGATGATGAGATGAACATTTTCATCAACCTCACCAAGGATGAGTTT
GTAGAACTCCGAGCCCTGGTCATTGAGATGGTGTTGGCCACAGACATGTCCTGCCATTTC
CAGCAAGTGAAGACCATGAAGACAGCCTTGCAACAGCTGGAGAGGATTGACAAGCCCAAG
GCCCTGTCTCTACTGCTCCATGCTGCTGACATCAGCCACCCAACCAAGCAGTGGTTGGTC
CACAGCCGTTGGACCAAGGCCCTCATGGAGGAATTCTTCCGTCAGGGTGACAAGGAGGCA
GAGTTGGGCCTGCCCTTTTCTCCACTCTGTGACCGCACTTCCACTCTAGTGGCACAGTCT
CAGATAGGGTTCATCGACTTCATTGTGGAGCCCACATTCTCTGTGCTGACTGACGTGGCA
GAGAAGAGTGTTCAGCCCCTGGCGGATGAGGACTCCAAGTCTAAAAACCAGCCCAGCTTT
CAGTGGCGCCAGCCCTCTCTGGATGTGGAAGTGGGAGACCCCAACCCTGATGTGGTCAGC
TTTCGTTCCACCTGGGTCAAGCGCATTCAGGAGAACAAGCAGAAATGGAAGGAACGGGCA
GCAAGTGGCATCACCAACCAGATGTCCATTGACGAGCTGTCCCCCTGTGAAGAAGAGGCC
CCCCCATCCCCTGCCGAAGATGAACACAACCAGAATGGGAATCTGGATTAG

# Drug_Target_6_General_Function:
Involved in catalytic activity

# Drug_Target_6_General_References:
1326532	Repaske DR, Swinnen JV, Jin SL, Van Wyk JJ, Conti M: A polymerase chain reaction strategy to identify and clone cyclic nucleotide phosphodiesterase cDNAs. Molecular cloning of the cDNA encoding the 63-kDa calmodulin-dependent phosphodiesterase. J Biol Chem. 1992 Sep 15;267(26):18683-8.
8855339	Jiang X, Li J, Paskind M, Epstein PM: Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11236-41.
9419816	Yu J, Wolda SL, Frazier AL, Florio VA, Martins TJ, Snyder PB, Harris EA, McCaw KN, Farrell CA, Steiner B, Bentley JK, Beavo JA, Ferguson K, Gelinas R: Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell Signal. 1997 Nov;9(7):519-29.

# Drug_Target_6_HGNC_ID:
HGNC:8775

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
5692

# Drug_Target_6_Locus:
12q13

# Drug_Target_6_Molecular_Weight:
61380

# Drug_Target_6_Name:
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B

# Drug_Target_6_Number_of_Residues:
536

# Drug_Target_6_PDB_ID:
1TAZ

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00233	PDEase_I
PF08499	PDEase_I_N

# Drug_Target_6_Protein_Sequence:
>Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
MELSPRSPPEMLEESDCPSPLELKSAPSKKMWIKLRSLLRYMVKQLENGEINIEELKKNL
EYTASLLEAVYIDETRQILDTEDELQELRSDAVPSEVRDWLASTFTQQARAKGRRAEEKP
KFRSIVHAVQAGIFVERMFRRTYTSVGPTYSTAVLNCLKNLDLWCFDVFSLNQAADDHAL
RTIVFELLTRHNLISRFKIPTVFLMSFLDALETGYGKYKNPYHNQIHAADVTQTVHCFLL
RTGMVHCLSEIELLAIIFAAAIHDYEHTGTTNSFHIQTKSECAIVYNDRSVLENHHISSV
FRLMQDDEMNIFINLTKDEFVELRALVIEMVLATDMSCHFQQVKTMKTALQQLERIDKPK
ALSLLLHAADISHPTKQWLVHSRWTKALMEEFFRQGDKEAELGLPFSPLCDRTSTLVAQS
QIGFIDFIVEPTFSVLTDVAEKSVQPLADEDSKSKNQPSFQWRQPSLDVEVGDPNPDVVS
FRSTWVKRIQENKQKWKERAASGITNQMSIDELSPCEEEAPPSPAEDEHNQNGNLD

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Has a preference for cGMP as a substrate

# Drug_Target_6_SwissProt_ID:
Q01064

# Drug_Target_6_SwissProt_Name:
PDE1B_HUMAN

# Drug_Target_6_Synonyms:
63 kDa Cam-PDE
Cam-PDE 1B
EC 3.1.4.17

# Drug_Target_6_Theoretical_pI:
5.22

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
2981533	Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
ADRA1A

# Drug_Target_7_GenBank_ID_Gene:
D25235

# Drug_Target_7_GenBank_ID_Protein:
433201

# Drug_Target_7_GeneCard_ID:
ADRA1A

# Drug_Target_7_Gene_Name:
ADRA1A

# Drug_Target_7_Gene_Sequence:
>1401 bp
ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG
GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG
GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC
ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG
CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC
ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC
TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG
AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA
CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG
GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC
CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT
GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC
GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG
CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC
TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT
TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC
ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC
TTGAGAATCCAGTGTCTCCGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG
CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA
TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC
TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC
ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGGAGGTCTGCTGCTGTGTAGGGCCCTCAACC
CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT
GAGAACGGGGAGGAAGTCTAG

# Drug_Target_7_General_Function:
Involved in alpha1-adrenergic receptor activity

# Drug_Target_7_General_References:
7737411	Hirasawa A, Shibata K, Horie K, Takei Y, Obika K, Tanaka T, Muramoto N, Takagaki K, Yano J, Tsujimoto G: Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett. 1995 Apr 24;363(3):256-60.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8024574	Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1296-304.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
8396931	Hirasawa A, Horie K, Tanaka T, Takagaki K, Murai M, Yano J, Tsujimoto G: Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor. Biochem Biophys Res Commun. 1993 Sep 15;195(2):902-9.
8564208	Tseng-Crank J, Kost T, Goetz A, Hazum S, Roberson KM, Haizlip J, Godinot N, Robertson CN, Saussy D: The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol. 1995 Aug;115(8):1475-85.
9490024	Chang DJ, Chang TK, Yamanishi SS, Salazar FH, Kosaka AH, Khare R, Bhakta S, Jasper JR, Shieh IS, Lesnick JD, Ford AP, Daniels DV, Eglen RM, Clarke DE, Bach C, Chan HW: Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms. FEBS Lett. 1998 Jan 30;422(2):279-83.

# Drug_Target_7_HGNC_ID:
HGNC:277

# Drug_Target_7_HPRD_ID:
00081

# Drug_Target_7_ID:
556

# Drug_Target_7_Locus:
8p21-p11.2

# Drug_Target_7_Molecular_Weight:
51487

# Drug_Target_7_Name:
Alpha-1A adrenergic receptor

# Drug_Target_7_Number_of_Residues:
466

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Amlodipine Pathway	SMP00376
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Carvedilol Pathway	SMP00367
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Enalapril Pathway	SMP00148
Felodipine Pathway	SMP00377
Fosinopril Pathway	SMP00149
Isradipine Pathway	SMP00378
Labetalol Pathway	SMP00368
Lisinopril Pathway	SMP00150
Moexipril Pathway	SMP00151
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Perindopril Pathway	SMP00152
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_7_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_7_Protein_Sequence:
>Alpha-1A adrenergic receptor
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins

# Drug_Target_7_SwissProt_ID:
P35348

# Drug_Target_7_SwissProt_Name:
ADA1A_HUMAN

# Drug_Target_7_Synonyms:
Alpha 1A- adrenoreceptor
Alpha 1A-adrenoceptor
Alpha adrenergic receptor 1c
Alpha-1C adrenergic receptor

# Drug_Target_7_Theoretical_pI:
9.23

# Drug_Target_7_Transmembrane_Regions:
28-51
65-88
100-122
144-167
182-205
274-297
306-329

# Drug_Target_8_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
2981533	Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
ADRA1B

# Drug_Target_8_GenBank_ID_Gene:
M99589

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
ADRA1B

# Drug_Target_8_Gene_Name:
ADRA1B

# Drug_Target_8_Gene_Sequence:
Not Available

# Drug_Target_8_General_Function:
Involved in alpha1-adrenergic receptor activity

# Drug_Target_8_General_References:
1328250	Ramarao CS, Denker JM, Perez DM, Gaivin RJ, Riek RP, Graham RM: Genomic organization and expression of the human alpha 1B-adrenergic receptor. J Biol Chem. 1992 Oct 25;267(30):21936-45.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.

# Drug_Target_8_HGNC_ID:
HGNC:278

# Drug_Target_8_HPRD_ID:
00080

# Drug_Target_8_ID:
632

# Drug_Target_8_Locus:
5q23-q32

# Drug_Target_8_Molecular_Weight:
56837

# Drug_Target_8_Name:
Alpha-1B adrenergic receptor

# Drug_Target_8_Number_of_Residues:
520

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_8_Protein_Sequence:
>Alpha-1B adrenergic receptor
MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAI
VGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDI
WAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGP
LLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAG
VMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVV
GMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFV
RILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRT
LPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLT
EPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system

# Drug_Target_8_SwissProt_ID:
P35368

# Drug_Target_8_SwissProt_Name:
ADA1B_HUMAN

# Drug_Target_8_Synonyms:
Alpha 1B- adrenoreceptor
Alpha 1B-adrenoceptor

# Drug_Target_8_Theoretical_pI:
9.79

# Drug_Target_8_Transmembrane_Regions:
46-70
84-105
116-141
162-182
202-224
296-319
327-340

# Drug_Target_9_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
2981533	Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
ADRA1D

# Drug_Target_9_GenBank_ID_Gene:
M76446

# Drug_Target_9_GenBank_ID_Protein:
177807

# Drug_Target_9_GeneCard_ID:
ADRA1D

# Drug_Target_9_Gene_Name:
ADRA1D

# Drug_Target_9_Gene_Sequence:
>1719 bp
ATGACTTTCCGCGATCTCCTGAGCGTCAGTTTCGAGGGACCCCGCCCGGACAGCAGCGCA
GGGGGCTCCAGCGCGGGCGGCGGCGGGGGCAGCGCGGGCGGCGCGGCCCCCTCGGAGGGC
CCGGCGGTGGGCGGCGTGCCGGGGGGCGCGGGCGGCGGCGGCGGCGTGGTGGGCGCAGGC
AGCGGCGAGGACAACCGGAGCTCCGCGGGGGAGCCGGGGAGCGCGGGCGCGGGCGGCGAC
GTGAATGGCACGGCGGCCGTCGGGGGACTGGTGGTGAGCGCGCAGGGCGTGGGCGTGGGC
GTCTTCCTGGCAGCCTTCATCCTTATGGCCGTGGCAGGTAACCTGCTTGTCATCCTCTCA
GTGGCCTGCAACCGCCACCTGCAGACCGTCACCAACTATTTCATCGTGAACCTGGCCGTG
GCCGACCTGCTGCTGAGCGCCACCGTACTGCCCTTCTCGGCCACCATGGAGGTTCTGGGC
TTCTGGGCCTTTGGCCGCGCCTTCTGCGACGTATGGGCCGCCGTGGACGTGCTGTGCTGC
ACGGCCTCCATCCTCAGCCTCTGCACCATCTCCGTGGACCGGTACGTGGGCGTGCGCCAC
TCACTCAAGTACCCAGCCATCATGACCGAGCGCAAGGCGGCCGCCATCCTGGCCCTGCTC
TGGGTCGTAGCCCTGGTGGTGTCCGTAGGGCCCCTGCTGGGCTGGAAGGAGCCCGTGCCC
CCTGACGAGCGCTTCTGCGGTATCACCGAGGAGGCGGGCTACGCTGTCTTCTCCTCCGTG
TGCTCCTTCTACCTGCCCATGGCGGTCATCGTGGTCATGTACTGCCGCGTGTACGTGGTC
GCGCGCAGCACCACGCGCAGCCTCGAGGCAGGCGTCAAGCGCGAGCGAGGCAAGGCCTCC
GAGGTGGTGCTGCGCATCCACTGTCGCGGCGCGGCCACGGGCGCCGACGGGGCGCACGGC
ATGCGCAGCGCCAAGGGCCACACCTTCCGCAGCTCGCTCTCCGTGCGCCTGCTCAAGTTC
TCCCGTGAGAAGAAAGCGGCCAAGACTCTGGCCATCGTCGTGGGTGTCTTCGTGCTCTGC
TGGTTCCCTTTCTTCTTTGTCCTGCCGCTCGGCTCCTTGTTCCCGCAGCTGAAGCCATCG
GAGGGCGTCTTCAAGGTCATCTTCTGGCTCGGCTACTTCAACAGCTGCGTGAACCCGCTC
ATCTACCCCTGTTCCAGCCGCGAGTTCAAGCGCGCCTTCCTCCGTCTCCTGCGCTGCCAG
TGCCGTCGTCGCCGGCGCCGCCGCCCTCTCTGGCGTGTCTACGGCCACCACTGGCGGGCC
TCCACCAGCGGCCTGCGCCAGGACTGCGCCCCGAGTTCGGGCGACGCGCCCCCCGGAGCG
CCGCTGGCCCTCACCGCGCTCCCCGACCCCGACCCCGAACCCCCAGGCACGCCCGAGATG
CAGGCTCCGGTCGCCAGCCGTCGAAAGCCACCCAGCGCCTTCCGCGAGTGGAGGCTGCTG
GGGCCGTTCCGGAGACCCACGACCCAGCTGCGCGCCAAAGTCTCCAGCCTGTCGCACAAG
ATCCGCGCCGGGGGCGCGCAGCGCGCAGAGGCAGCGTGCGCCCAGCGCTCAGAGGTGGAG
GCTGTGTCCCTAGGCGTCCCACACGAGGTGGCCGAGGGCGCCACCTGCCAGGCCTACGAA
TTGGCCGACTACAGCAACCTACGGGAGACCGATATTTAA

# Drug_Target_9_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_9_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
1656955	Bruno JF, Whittaker J, Song JF, Berelowitz M: Molecular cloning and sequencing of a cDNA encoding a human alpha 1A adrenergic receptor. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1485-90.
7746284	Esbenshade TA, Hirasawa A, Tsujimoto G, Tanaka T, Yano J, Minneman KP, Murphy TJ: Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells. Mol Pharmacol. 1995 May;47(5):977-85.
7815325	Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.
8024574	Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1296-304.
8183249	Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.

# Drug_Target_9_HGNC_ID:
HGNC:280

# Drug_Target_9_HPRD_ID:
00079

# Drug_Target_9_ID:
789

# Drug_Target_9_Locus:
20p13

# Drug_Target_9_Molecular_Weight:
60463

# Drug_Target_9_Name:
Alpha-1D adrenergic receptor

# Drug_Target_9_Number_of_Residues:
572

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_9_Protein_Sequence:
>Alpha-1D adrenergic receptor
MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAG
SGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILS
VACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCC
TASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVP
PDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKAS
EVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLC
WFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQ
CRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEM
QAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVE
AVSLGVPHEVAEGATCQAYELADYSNLRETDI

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium

# Drug_Target_9_SwissProt_ID:
P25100

# Drug_Target_9_SwissProt_Name:
ADA1D_HUMAN

# Drug_Target_9_Synonyms:
Alpha 1D- adrenoreceptor
Alpha 1D-adrenoceptor
Alpha adrenergic receptor 1a
Alpha-1A adrenergic receptor

# Drug_Target_9_Theoretical_pI:
9.44

# Drug_Target_9_Transmembrane_Regions:
96-121
134-159
170-192
214-238
252-275
349-373
381-405

#END_DRUGCARD DB00622
